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Abstract 
Intensity-modulated radiation therapy (IMRT) uses non-uniform beam intensities within 
a radiation field to provide patient-specific dose shaping, resulting in a dose distribution 
that conforms tightly to the planning target volume (PTV). Unavoidable geometric 
uncertainty arising from patient repositioning and internal organ motion can lead to lower 
conformality index (CI) during treatment delivery, a decrease in tumor control probability 
(TCP) and an increase in normal tissue complication probability (NTCP). The CI of the 
IMRT plan depends heavily on steep dose gradients between the PTV and organ at risk 
(OAR). Geometric uncertainties reduce the planned dose gradients and result in a less 
steep or “blurred” dose gradient. The blurred dose gradients can be maximized by 
constraining the dose objective function in the static IMRT plan or by reducing geometric 
uncertainty during treatment with corrective verification imaging.  
Internal organ motion and setup error were evaluated simultaneously for 118 individual 
patients with implanted fiducials and MV electronic portal imaging (EPI). A Gaussian 
probability density function (PDF) is reasonable for modeling geometric uncertainties as 
indicated by the 118 patients group. The Gaussian PDF is patient specific and group 
standard deviation (SD) should not be used for accurate treatment planning for individual 
patients. In addition, individual SD should not be determined or predicted from small 
imaging samples because of random nature of the fluctuations. Frequent verification 
imaging should be employed in situations where geometric uncertainties are expected. 
Cumulative PDF data can be used for re-planning to assess accuracy of delivered dose. 
Group data is useful for determining worst case discrepancy between planned and 
delivered dose. The margins for the PTV should ideally represent true geometric 
uncertainties. The measured geometric uncertainties were used in this thesis to assess 
PTV coverage, dose to OAR, equivalent uniform dose per fraction (EUDf ) and NTCP. 
The dose distribution including geometric uncertainties was determined from integration 
of the convolution of the static dose gradient with the PDF. Integration of the convolution 
of the static dose and derivative of the PDF can also be used to determine the dose 
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including geometric uncertainties although this method was not investigated in detail. 
Local maximum dose gradient (LMDG) was determined via optimization of dose 
objective function by manually adjusting DVH control points or selecting beam numbers 
and directions during IMRT treatment planning. Minimum SD (SDmin) is used when 
geometric uncertainty is corrected with verification imaging. Maximum SD (SDmax ) is 
used when the geometric uncertainty is known to be large and difficult to manage. SDmax 
was 4.38 mm in anterior-posterior (AP) direction, 2.70 mm in left-right (LR) direction 
and 4.35 mm in superior-inferior (SI) direction; SDmin was 1.1 mm in all three directions 
if less than 2 mm threshold was used for uncorrected fractions in every direction. 
EUDf is a useful QA parameter for interpreting the biological impact of geometric 
uncertainties on the static dose distribution. The EUDf has been used as the basis for the 
time-course NTCP evaluation in the thesis. Relative NTCP values are useful for 
comparative QA checking by normalizing known complications (e.g. reported in the 
RTOG studies) to specific DVH control points. For prostate cancer patients, rectal 
complications were evaluated from specific RTOG clinical trials and detailed evaluation 
of the treatment techniques (e.g. dose prescription, DVH, number of beams, bean angles). 
Treatment plans that did not meet DVH constraints represented additional complication 
risk. Geometric uncertainties improved or worsened rectal NTCP depending on 
individual internal organ motion within patient. 
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1.1    Overview and Thesis Outline 
The goal of radiation therapy is to deliver a highly conformal and lethal absorbed dose to 
a prescribed target volume and to spare surrounding healthy tissue as much as possible. 
Using commercial treatment planning systems available presently, the patient anatomy is 
assumed to be static over the course of treatment (i.e. 5~6 weeks). Fundamentally, 
reproducibility of patient setup and internal organ motion leads to discrepancies between 
the planned (intended) and actual delivered dose to the patient. These discrepancies can 
have a significant impact on treatment outcome and should be accounted for in the 
treatment planning process. Dose planning, including a 3D dose calculation performed by 
the treatment planning system and a dose prescription from the radiation oncologist, 
assumes stable anatomy. During treatment delivery, however, geometric uncertainties 
arising from patient repositioning and internal organ motion are unavoidable. For prostate 
patients, anisotropic motions with magnitudes of 1–2 cm have been reported in several 
studies, with the greatest displacement along the superior-inferior direction (Ten Haken 
1991, Schild 1993, Balter 1995, Crook 1995, van Herk 1995, Lebesque 1995, Roeske 
1995, Beard 1996, Althof 1996, Melian 1997). The position of the prostate is also 
affected by patient positioning, e.g., supine versus prone (Stroom 1999), and by rectal 
and bladder distension (Ten Haken 1991, Schild 1993). Balter (2000) showed that 
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craniocaudal motion was largest for the prostate. Geometric uncertainty causes the target 
volume to move in and out of the high dose region of the radiation fields which can lead 
to a compromise in target dose coverage and a decrease in tumor control probability 
(TCP). Similar uncertainty associated with healthy organs adjacent to the target volume 
can lead to an increase in normal tissue complication probability (NTCP).  
Patient positioning & immobilization 
Imaging for RT planning 
Target & normal tissue delineation 
Formulation of dose prescription with constraints 
Inverse planning 
Data transfer from planning system to treatment delivery system 
Dosimetry confirmation 
Verification Imaging 
Computer controlled dose delivery 
ART 
 
Figure 1. 1: The steps in IMRT treatment planning process. 
The process of radiation therapy for malignant disease is complex and involves many 
steps (Van Dyk 1999, 2005) as shown in Figure 1.1. The overall process leading to 
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patient treatment begins with patient positioning and immobilization and includes other 
important component steps of imaging for target delineation, definition of dose 
constraints, inverse planning, dosimetry verification and finally dose delivery. 
In each of the process steps there will be uncertainties that should be quantified and 
managed (reduced, eliminated, and/or included in the dose calculation of total absorbed 
dose). It is important that each step of the process is executed with the greatest accuracy 
possible. The success or failure of a radiation therapy treatment is highly dependent upon 
the accuracy of the dose delivered. Even small deviations (reductions) from the plan of 
the prescribed dose to the target volume can have a direct impact on treatment outcome.  
At the same time, small deviations (increases) in dose delivered to radio-sensitive healthy 
organs or tissues can significantly increase the probability of normal tissue complications. 
Overall, the total dose delivered should be accurate to within 5% (ICRU report 24 1976), 
and any potential method to increase the accuracy in the dose calculation or dose delivery 
should be investigated. Uncertainties of 5% or greater may jeopardize the intent of the 
treatment and represent significant risk to patient. The outcome of clinical trials is 
dependent on dose accuracy, 5% accuracy is desirable and assuming that uncertainties in 
each procedure are random in nature, then the required accuracy for each step is 2.5% 
(ICRU report 50 1993, ICRU report 62 1999, Van Dyk 1999). 
Historically, radiation therapy predominantly employed parallel-opposed rectangular 
fields with cerrobend blocks, which remain the foundation for conformal radiation 
therapy (CRT). Generous margins have been applied to the target volume to compensate 
for general uncertainties including setup error and organ motion (ICRU report 50 1993, 
ICRU report 62 1999). Unavoidably, situations arise where the margins of the clinical 
target volume (CTV) and critical structures (rectum and bladder for prostate patient, for 
example) overlap. Under realistic situation involving target and organ at risk (OAR) 
intersection and movement, conventional treatment planning systems do not always 
calculate the dose accurately. Dose calculation incorporating organ motion will improve 
agreement between planned and delivered doses ideally leading to higher TCP and lower 
NTCP.   
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Newer paradigms for radiation therapy, for example, Intensity Modulated Radiation 
Therapy (IMRT), Image Guided Radiation Therapy (IGRT) and Adaptive Radiation 
Therapy (ART), require detailed anatomical segmentation. Unfortunately, studies of 
inter-observer variability in defining radiation target suggest that gross tumor volumes 
(GTVs) are not always reproducible (Cazzaniga 1998, Rasch 1999). 
With the advent of improved medical imaging technologies for radiation therapy 
planning (RTP), including Computed Tomography (CT), Positron Emission Tomography 
(PET), Magnetic Resonance (MR), Ultrasound (US), and verification imaging 
technologies including Cone Beam CT (CBCT) and a-Si MV electronic portal imaging 
(EPI) for repositioning and re-planning guidance, it is possible to reduce the margin 
because of greater confidence in CTV delineation and greater confidence in delivering 
dose to the planning target volume (PTV). Improved medical imaging technologies, with 
the capability for image co-registration and fusion offer improved resolution and contrast 
between malignant and healthy tissues. The improved verification imaging systems lead 
to greater confidence in aligning treatment beams with the target.  Newer technology for 
radiation delivery, for example, a linear accelerator (linac) with Dynamic Multileaf 
Collimator (DMLC), Helical Tomography, Cyberknife and High Dose Rate (HDR) 
Brachytherapy offer improved ability to sculpt dose with greater precision, and lead to 
increase confidence in the delivery of dose to the target since the radiation “travels” with 
the target.  
Improved 3 dimensional (3D) dose calculations (optimization of objective functions, dose 
assessment tools including 2 dimensional (2D) dose analyses by image slice, multi-planar 
dose reconstruction (MPR), and dose volume histogram (DVH)), collectively 
demonstrate the benefits for 3D CRT. However, DVH does not provide spatial 
information about the dose distribution, and optimized IMRT plans do not always 
develop a high local maximum dose gradient (LMDG) between the PTV and OAR. The 
accuracy of the dose distribution based on static anatomy is limited because of exclusion 
of the blurring effects of geometric uncertainties (internal organ motion and setup error). 
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The assessment of planned versus delivered dose is necessary because of the impact of 
geometric uncertainties. 
The inclusion of geometric uncertainties in dose calculations has been approached using 
several methods, many of them employing convolution techniques (Leong 1987, Lind 
1993, Rudat 1994 1996, Bel 1996, Keall 1999, Lujan 1999a 1999b, Stroom 1999, Li 
2000, McCarter 2000, McKenzie 2000a 2000b, van Herk 2000 2002, Booth 2001, O'Dell 
2002). Recently Craig et al (2003a, 2003b) have shown that for deep seated tumors (e.g. 
prostate) it is reasonable to convolve the static dose distribution with a  probability 
density function (PDF) characterizing geometric uncertainties to obtain a modified dose 
distribution. Using this approach, however, it is not easy to interpret the modified dose 
distribution in terms of magnitude and position of the motion effects. There is no direct 
parametric connection between the convolution integral and the static dose distribution 
that could be used to manage geometric uncertainties from the perspective of optimized 
dose (DVH does not contain spatial information). One of the main objective of this thesis 
is to develop a parametric connection between the convolution integral of dose with PDF; 
namely the dose gradient rDG v∂∂= /00 . Another important area of focus is on careful 
clinical assessment of the PDF using modern imaging technology and surgically 
implanted fiducial markers. 
The thesis objectives in each chapter are shown in Table 1.1 and the flow chart of the 
thesis is shown in Figure 1.2. The dose distribution including geometric uncertainties was 
determined from the static dose gradient and motion PDF (Chapter 3, published in Jiang 
et al 2007a). Geometric uncertainty was determined from EPID images including fiducial 
markers for 118 patients; including a study of 20 patients with simultaneous fraction-to-
fraction evaluation of setup error and organ motion (Chapter 2, published in Jiang et al 
2007c). Geometric uncertainties were shown to reduce the static dose gradient and result 
in a blurred dose gradient (Chapter 3, published in Jiang et al 2007a, 2007b). The blurred 
dose gradient can be maximized by improving the LMDG in the static plan (Chapter 4, 
published in Jiang et al 2006a, 2007d) or by reducing geometric uncertainty during 
treatment with corrective verification imaging (Chapter 2, published in Jiang et al 2007c). 
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The rectal positional variations were evaluated by equivalent uniform dose per fraction 
(EUDf) deviations, and NTCP changing with fraction numbers was evaluated with and 
without motion (Chapter 5, published in Jiang et al 2006b).  
Table 1. 1: The topics in each chapter of the thesis. 
Chapters Topics 
PDF for description of geometric uncertainties during radiation 
treatment 




Determination of biological effects, EUDf, NTCP with uncertainties 
Evaluation of Gaussian PDF (MV EPID with fiducials: 118 patients) Chapter 2 
IGRT Bony vs. prostate motion (simultaneous fraction-to-fraction 
evaluation of setup error and organ motion for 20 patients)  




Blurred dose profile; 
Improving static LMDG in IMRT optimization Chapter 4 
LMDG & IMRT Reducing uncertainty with corrective verification imaging 
EUD per fraction (EUDf) Chapter 5 
Biological 
Effect of Motion NTCP fraction-to-fraction (NTCPf) 
Summary and conclusion  Chapter 6 





































DVH Ctrl Points 
High LMDG 
Rectal DVH per 
Fraction; 
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1.2   Uncertainties in Prostate Radiation 
Therapy  
1.2.1    Radiation and radiation biology 
Radiation can be classified as directly or indirectly ionizing. All the charged particles, 
such as electrons, protons, α-particles and heavy charged ions are directly ionizing, that 
is, provided the individual particles have sufficient kinetic energy, they can directly 
disrupt the atom structure of absorber through which they pass and produce chemical and 
biological changes. Electromagnetic radiations (x- and γ- rays) are indirectly ionizing. 
They do not produce chemical and biological damage themselves, but when they are 
absorbed in the material through which they pass they give up their energy to produce 
fast-moving charged particles.  
When an x-ray beam (i.e. a beam of photons) passes into an absorbing medium such as 
body tissues, some of the energy is transferred to the medium where it may produce 
biological damage. The energy deposited per unit mass of the medium is known as the 
absorbed dose. The unit of absorbed dose is Gray (Gy). The events that result in this 
absorbed dose and subsequent biological damage are complicated and illustrated in a 
simplified way in Figure 1.3 (Johns and Cunningham 1994). The first step involves the 
collision between a photon and some electron in the body, resulting in the scattering of 
some radiation and the setting in motion of a high speed electron (Figure 1.3 A). In 
traveling through the tissue, the high speed electron produced a track along which 
ionization occurs, excitation of atoms takes place, and molecular bonds are broken 
(Figure 1.3 B). All of these result in biological damage. Most of the energy is converted 
into heat, producing no biological effect. Some of the high speed electrons may suffer a 
collision with a nucleus and produce bremsstrahlung. This bremsstrahlung, as well as the 
scattered radiation, can undergo interactions in the same way as the original photon. 
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Usually, some 30 interactions are required before all the energy of the photons is 
converted into electronic motion. The physics of the absorption process is over in 10-15 
second; the chemistry takes longer since the lifetime of free radicals is about 10-5 second; 
the biology takes days to months for cell killing, years for carcinogenesis, and 
generations for heritable damage. 
X-ray photons interact with the absorber to produce high speed electrons by three 
important mechanisms known as the photoelectric process, Compton scattering, and pair 
production. The process by which x-ray photons are absorbed depends on the energy of 
the photons and the chemical composition of the absorbing material. The biological 
effects of radiation result principally from damage to DNA, which is the critical target. 
When any form of radiation is absorbed in biological material, the atoms of the target 
itself may be ionized or excited, thus initiating the chain of events that leads to a 
biological change. This is the direct action of radiation. It is the dominant process when 
radiations with high linear energy transfer (LET), such as neutrons or α-particles, are 
considered. Alternatively, the radiation may interact with other atoms and molecules in 
the cell (particularly water) to produce free radicals that are able to diffuse far enough to 
reach and damage the critical targets. This is the indirect action of radiation. Biological 
effects of x-rays may be due to direct action (the recoil electron directly ionizes the target 
molecule) or indirect action (the recoiled electron interacts with water to produce a 
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(A) and (B) 
Radiation (x rays) enters biological system 
Primary interaction 
occurs with an electron 
Ionization, excitation, breaking 














High speed electron giving 
absorbed energy 
 
Figure 1. 3: The absorption of energy from radiation resulting in biological damage 
(Johns and Cunningham 1994). 
1.2.2   Prostate cancer and treatment 
Prostate cancer is the abnormal growth of cells in a man's prostate gland. The prostate 
produces semen fluid in the male. Prostate cancer is common in men older than 65. It 
usually grows slowly and can take years to grow large enough to cause any problems. 
Most cases are treatable, because they are found with screening tests before the cancer 
has spread to other parts of the body. Experts don't know what causes prostate cancer, but 
they believe that the age, family history (genetics), and race affect the chances of getting 
it, and diet may exert an indirect influence. About 70–75% of prostate cancers arise in the 
peripheral zone of the gland, mainly in a posterior location, of the remaining cases, 15% 
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derive from the central zone and 10–15% from the transitional zone (Qian 1997). Prostate 
cancer may spread locally, by direct invasion of seminal vesicles, urinary bladder or 
surrounding tissues (Cotran 1999). 
A prostate-specific antigen (PSA) test measures the amount of prostate-specific antigen 
in the blood. PSA is released into a man's blood by prostate gland. Healthy men have low 
amounts of PSA in the blood. The amount of PSA in the blood normally increases as a 
man's prostate enlarges with age. PSA may increase as a result of an injury, a digital 
rectal exam, sexual activity (ejaculation), inflammation of the prostate gland (prostatitis), 
or prostate cancer. In the past, most experts viewed PSA levels less than 4 ng/mL as 
normal. Due to the findings from more recent studies, some recommend lowering the 
cutoff levels that determine if a PSA value is normal or elevated. Some researchers 
encourage using less than 2.5 or 3 ng/mL as a cutoff for normal values, particularly in 
younger patients. Younger patients tend to have smaller prostates and lower PSA values, 
so any elevation of the PSA in younger men above 2.5 ng/mL is a cause for concern. 
Prostate cancer is often graded using the Gleason score, on a scale of 2 to 10. The 
Gleason score is considered a powerful tool for predicting how aggressive a tumor will 
be. The higher the Gleason score, the more likely the tumor is to grow rapidly and spread 
(metastasize) to other parts of the body. A Gleason score of 2 to 6 indicates well-
differentiated tumors with cells that are expected to grow slowly and not spread readily. 
A Gleason score of 7 indicates moderately differentiated tumor cells. A Gleason score of 
8 to 10 indicates poorly differentiated tumors with cells that are likely to grow rapidly 
and spread to other parts of the body. 
Many kinds of cancer have staging systems that help physicians decide what treatments 
to choose. The stages of cancer are based on where and how far it has grown. The most 
common staging system for prostate cancer is the TNM system, which labels the cancer 
in three categories: the size of the tumor (T), the spread of the cancer to lymph nodes (N), 
and the spread of the cancer to other parts of the body (M, for metastasis). Besides using 
the TNM labels, the physician also will give the cancer a Gleason score. A Gleason score 
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is a way to describe differences in prostate cancer cells. Prostate cancer cells that have a 
low Gleason score grow more slowly than cells that have a higher score. Once the TNM 
and Gleason score information is collected, the physician can tell what stage the cancer is 
in, what treatment is best, and what the outlook is for being cured. The stages of prostate 
cancer are classified as following: 
Stage I: T1a, N0, M0, low Gleason score (2 to 4); the cancer is still within the prostate 
and has not spread to lymph nodes or elsewhere in the body. The cancer was found 
during a transurethral resection, it had a low Gleason score (2 to 4), and less than 5% of 
the tissue was cancerous.  
Stage II: T1a, N0, M0, Gleason score of 5 to 10; OR T1b-T2, N0, M0, any Gleason 
score; the cancer is still within the prostate and has not spread to the lymph nodes or 
elsewhere in the body, and one of the following applies: it was found during a 
transurethral resection and has an intermediate or high Gleason score (5 or higher), or 
more than 5% of the tissue contained cancer; or  it was discovered because of a high PSA 
level, cannot be felt on digital rectal exam or seen on transrectal ultrasound, and was 
diagnosed by needle biopsy; or  it can be felt on digital rectal exam or seen on transrectal 
ultrasound.  
Stage III: T3, N0, M0, any Gleason score (2 to 10); the cancer has begun to spread 
outside the prostate and may have spread to the seminal vesicles, but it has not spread to 
the lymph nodes or elsewhere in the body.  
Stage IV: T4, N0, M0;OR any T, N1, M0;OR any T, any N, M1 (any Gleason score); one 
or more of the following apply: the cancer has spread to tissues next to the prostate (other 
than the seminal vesicles), such as the bladder's external sphincter (muscle that helps 
control urination), rectum, and/or the wall of the pelvis; and/or it has spread to the lymph 
nodes; and/or it has spread to other, more distant sites in the body.  
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There are three risk levels according to the stages of prostate cancer: Favorable risk (T1-
T2a): a Gleason score less than 6, and a pretreatment PSA less than 10 ng/mL; 
Intermediate risk (T2b or T2c): a Gleason score less than 7, or a pretreatment PSA 
between 10~20 ng/mL,; Unfavorable risk (T3a or higher): a Gleason score: 8 ~10, or a 
pretreatment PSA higher than 20 ng/mL. 
If prostate cancer is truly confined to the prostate, it is curable with surgery or radiation. 
However, in order to benefit from curative treatment, a patient's life expectancy may need 
to be 10-15 years. Patients diagnosed with early stage prostate cancer must choose 
between "watchful waiting", more aggressive treatment with radiation or surgery (radical 
prostatectomy), or participation in a clinical study. Unfortunately, well-controlled clinical 
studies comparing these treatment approaches have not been performed. Before making 
treatment recommendations, physicians who treat prostate cancer consider a number of 
aspects about the patient's disease that help predict whether the cancer is confined to the 
prostate (potentially curative) and how fast the cancer will grow. These aspects include 
the clinical stage of the cancer, the PSA level, and the appearance of the prostate cancer 
cells under the microscope (the Gleason score). Patients with early stage cancer, lower 
PSA levels and a low Gleason score have more treatment options available and a better 
chance of long-term survival. 
Grand River Regional Cancer Center (GRRCC) initiated a Stage I/II prospective study of 
radiation treatment of prostate cancer. Patients with intermediate and low-risk carcinoma 
of the prostate were identified for radiation treatment in this clinical trial as shown in 
Figure 1.4. The eligibility criteria included clinical stage T1b, T1c and T2, a Gleason 
score less than 8 and PSA levels less than or equal to 20 ng/ml. The goal of the study is to 
reduce acute and late side effects without compromising local tumor control. Dose 
escalation is proven to be effective for this disease, and IGRT plays an integral role in 
preparing these patients for accurate, reproducible treatments with daily online image 
verification.  
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T1b, T1c, T2 
N0, M0, 
Gleason < 8 
PSA ≤ 20 ng/ml 
Prostate cancer 
T1b, T1c, T2a 
Gleason ≤ 6 & 
PSA ≤ 10 ng/ml 
T2b or 
Gleason 7 or 
PSA > 10 ng/ml 
Low Risk Intermediate Risk  
 
Figure 1. 4: Radiation treatment at GRRCC for low and intermediate risk prostate 
cancer.  
1.2.3   Characterization of geometric uncertainties 
Geometric uncertainties are separated into two categories: variations in the positioning of 
the patient's bony anatomy with respect to the beam axes (often referred to as setup 
errors), and variations in the position of the target within the patient with respect to the 
bony structures (often referred to as organ motion).  
Most of the geometric uncertainty studies in external-beam radiation therapy have been 
performed using portal imaging to assess setup errors during treatments. Orthogonal 
Megavoltage and Kilovoltage imaging, with or without fiducial markers, can decrease 
setup error and target margins. The verification imaging, obtained before, during, or after 
treatment, records a patient’s position at the time of radiation therapy. It can guide the 
radiation beam and lead to repositioning of the patient prior to irradiation if 
misalignments are detected. Image-guidance strategies used to reduce setup error are 
generally classified as either online or offline procedures. An online approach acquires 
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and assesses information from daily imaging, typically before every treatment fraction. 
Simple corrections are implemented to compensate for deviations in patient’s position 
that exceed a predefined threshold before radiation delivery. An offline strategy refers to 
frequent acquisition of images without immediate intervention. When enough fractions 
have been administered (typically three or more), an offline statistical analysis calculates 
the systematic (mean) and random (standard deviation) components of the patient’s setup 
error. A correction for systematic error can be implemented for the remaining treatment 
fractions. Online correction strategies achieve a larger reduction in geometric errors 
compared with offline approaches, but require spending more effort and time at treatment 
delivery and require a higher imaging dose. With offline and online approaches, 
clinicians can re-plan an individual’s treatment during the radiation therapy course to 
account for patient-specific information acquired with image guidance. This practice is 
referred to as adaptive radiation therapy (ART). The reported magnitude of setup error is 
most certainly influenced by the particular setup technique performed at the particular 
institution. 
Many authors have reported on the uncertainty in the location of the prostate relative to 
bony anatomy. It is difficult to give any concrete comparison from the various studies 
because of the differences in methods and analysis employed by the authors. The 
characterization of prostate motion is difficult, and the small numbers of patients limit the 
scope of conclusions that can be drawn from any particular study. The reported range of 
organ motion varied by a factor of nearly 10 (Jaffray 1999). In a review of organ motion 
studies, Kutcher (1995) et al suggest that the larger number of data sets should be 
acquired to better characterize the motion and its dependence on other factors. 
Investigators have recommended caution in interpreting the results of organ motion 
studies. The variability in the reported results makes interpretation difficult. It is expected 
that the discrepancies among these studies are due to uncontrolled variables, such as 
changes in intra-abdominal pressure due for example to gas in the bowel, filling of the 
bladder, unspecified conditions, the use of immobilization cradles or the position of the 
patient. 
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1.2.4   Managing uncertainties with safety margins: 
ICRU formalism 
One of the important factors that has contributed to the success of 3D CRT is the 
standardization published in the International Commission on Radiation Units and 
Measurements (ICRU) Reports 50 and 62 (ICRU report 50 1993, ICRU report 62 1999). 
The reports gave the radiation oncology community a consistent nomenclature and a 
methodology for image-based treatment planning in which the physician specifies the 
volumes of tumor: GTV; clinical target volume (CTV): the volumes of suspected 
microscopic spread; and PTV: the marginal volumes necessary to account for setup 
variations and organ motion. 
ICRU Report 62 defined PTV by introducing the concept of an internal margin (IM) to 
take into account variations in size, shape, and position of the CTV in reference to the 
patient’s anatomic reference points, and also the concept of a setup margin (SM) to take 
into account all uncertainties in patient-beam positioning in reference to the treatment 
machine coordinate system. IM uncertainties are caused by physiologic variations (filling 
of rectum, motion etc) and are difficult or almost impossible to control from a practical 
point of view. SM uncertainties are related largely to technical factors that can be dealt 
with by more accurate setup and immobilization of the patient and improved mechanical 
stability of the machine. The internal target volume (ITV) represents the movements of 
the CTV referenced to the patient coordinate system and preferably should be rigidly 
related to bony structures.  
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Figure 1. 5: Schematic illustration of the volumes defined by ICRU Report 62: GTV, 
CTV, ITC, PTV, treated volume, and irradiated volume. 
 
GTV, CTV, ITC, PTV, treated volume and irradiated volume defined by ICRU Report 62 
are illustrated in Figure 1.5. Report ICRU 62 defined two dose volumes: the treated 
volume and the irradiated volume. The treated volume is the tissue volume that is 
planned to receive at least a dose specified by radiation oncology as being appropriate to 
achieve the purpose of the treatment; the irradiated volume is the tissue volume that 
receives a dose that is considered significant in relation to normal tissue tolerance. Purdy 
(2002, 2004) reviewed the development of the current ICRU volume definitions, and 
discussed the issues and compromises required when using these definitions in 3DCRT 
and IMRT planning. 
Safety margins can be decided based on geometric considerations. The simplest of these 
is to statistically select a margin as some number of standard deviations (SDs) of motion 
outside the target volume. The more sophisticated approach is presented by van Herk 
(2002) et al, in which they concluded that there is a substantial difference in systematic 
errors as compared with random errors, leading to an overall margin that is about a factor 
of 2 larger than that proposed by Goitein (1983). McKenzie et al (2002) propose a margin 
around OAR that is half the size of that which they propose to place around the target 
volume.  
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Large margins result in a high level of confidence that the CTV is adequately covered 
during treatment. Narrower margins and more conformal dose distributions are helpful to 
reduce the dose to the normal tissues and complications, but may on the other hand risk 
violation of the PTV concept. IMRT dose distributions can be shaped to conform much 
more closely to the PTV and to avoid OAR, thus introducing sharp dose gradients on the 
edge of the PTV. IMRT treatments are more sensitive to geometric uncertainties (Jaffray 
et al 1999). The uncertainties may result in tumor underdose or normal tissue overdose. 
Factors that primarily affect positional uncertainty in target and OAR are errors in target 
delineation, patient positioning or setup errors, and internal organ motion.  
Although much attention in recent years has focused on organ motion and setup error, 
errors in delineating the gross and clinical target volumes should also be considered when 
determining planning target volume margins. A number of studies (Roach et al 1996, 
1997, 1999, Tai 2002) have shown that there can be large differences in image 
interpretation among physicians and institutions. A lack of delineation protocols and 
understanding of radiological anatomy are frequent and important sources of error. It is 
known that the shape and size of the GTV can depend significantly on the imaging 
modality (Roach et al 1996, 1997, 1999). Roach et al (1996) compared the delineated 
prostate volumes using both CT and MRI for a series of patients and found significant 
volume differences in approximately one third of the cases, depending on the imaging 
modality used. Rasch et al (1997) concluded that MRI derived target volumes had less 
inter-observer variation than CT-only derived target volumes. In another study, Rasch et 
al (1999) compared GTVs defined using both CT and MRI, the target volume defined 
using CT and MRI was different than the volume defined using CT alone.   
With regard to organ motion, a review by Langen et al (2001) provided the most 
comprehensive compilation of organ motion data. Inter-fraction organ motion studies 
have focused mainly on the treatment of prostate cancer (Balter 1995, Roeske 1995, van 
Herk 1995, Althof 1996, Tinger 1998, Jiang 2007c) as shown in Table 1.3, whereas intra-
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fraction motion studies have focused on variations caused by respiratory motion (Balter 
1998, Hanley 1999) for disease in the thoracic and upper abdominal regions.  
 Table 1. 2: Prostate motion specified as one SD (mm) in the AP, LR and SI directions. 
       
Prostate Motion (1 SD) (mm) AP LR SI 
Jiang et al , seeds (2007c) 2.6 1.4 3.0 
Alasti et al, seeds (2001) 5.8 - 3.3 
Althof et al, seeds (1996) 1.5 0.8 1.7 
Antolak et al, CT (1998) 3.6 0.7 3.6 
Balter et al, seeds (1995) 2.3 0.9 1.9 
Crook et al, seeds (1995) 4.1 1.5 5.0 
Litzenberg et al, CT (2002) 2.4 1.9 2.1 
Melian et al, CT (1997) 4.0 1.2 3.1 
Roeske et al, CT (1995) 3.9 0.7 3.2 
Rudat et al, CT (1996) 3.7 1.9 - 
Schiffner et al, CT (2007) 2.1 0.9 2.4 
Tinger et al, CT (1998) 2.6 0.9 3.9 
Van Herk et al, CT (1995) 3.8 1.3 2.4 
Vigneault et al, seeds (1997) 3.5 1.9 3.6 
Wu et al, seeds (2001) 2.3 - 2.1 
 
The setup uncertainty is due to an inability to control all factors that influence the setup, 
such as weight loss, discomfort, tension, inconsistent full or empty of bladder and rectum 
etc. These factors may cause patient to a poor setup; and large setup error could lead to 
significant errors in dosimetric coverage of the target volume and possible overdosing of 
normal tissues in the dose escalation with conformal treatments. Herman (2001) surveys 
the clinical uses of electronic portal imaging device. Although the most widespread use 
has been to verify and correct positioning of skeletal anatomy, it has been increasingly 
used in prostate localization and correction with implanted fiducials.  
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The relationship between targeting uncertainty and choice of treatment margin has been 
reviewed by Kutcher (1995) et al. The margin used to create the PTV should not just be 
based strictly on target geometric uncertainty considerations, the OAR should also be 
taken into account. The margin is the result of tradeoffs that balance concerns for 
potential geometrical miss versus unacceptable toxicity. A serious limitation currently 
present with some IMRT planning systems occurs when a PTV overlaps with an OAR. 
The basis for choosing a margin between a tumor and OAR should not just be purely 
physical considerations, but also a biological consideration. An analysis using TCP and 
NTCP would be a natural way of approaching this problem. Herring (1970) et al 
summarized the sensitivity of tumor control and normal tissue complication rates to 
dosimetric variations. The dose delivered over the course of treatment should be within ± 
5%. Achieving this level of accuracy and precision requires that each step of the 
treatment process much be better than 5%. This requirement places stiff tolerances on 
both the precision of the clinical dosimetry and the geometric precision in delivery and 
planning. To achieve and maintain the desired level of precision, it is recommended that a 
system of treatment delivery be constructed that considers both dosimetric and geometric 
uncertainty factors. However, it is uncertain whether TCP/NTCP models correctly 
represent dose-response under conditions of inhomogeneous dose distributions often 
encountered in IMRT, especially in the case of when some part of the normal tissue is 
exposed to a small region of high dose (i.e. overlap with the tumor). Therefore, any 
optimization result based on biophysical modeling must be interpreted with great caution. 
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1.3   Image Guided Radiation Therapy 
(IGRT) 
1.3.1    Setup error and organ motion  
External-beam radiation therapy is a major treatment modality for prostate cancer. The 
treatment course typically consists of many fractions over several weeks. Geometric and 
anatomic variations occur throughout the treatment process. These uncertainties include 
setup error and organ motion. The prostate gland is located between the rectum and the 
bladder, the contents of which may change from day to day. The prostate position as well 
as its shape can change from fraction-to-fraction because of filling and emptying of the 
bladder and rectum.  
Previous studies that utilized multiple CT scans (Roeske 1995, Antolak 1998, Deurloo 
2005) during the treatment course showed that the organ motion is largely of random 
nature, although some evidence suggests radiation-induced changes occurring during a 
treatment course (Mechalakos 2002). In addition, setup errors based on marks placed on 
skin or immobilization device can be larger because the target depth for prostate cancer is 
greater than that for other tumor sites. These uncertainties can be either compensated for 
by use of safety margins or reduced by use of image guidance. 
To compensate for uncertainties, the ICRU recommends use of margins in treatment 
planning (ICRU report 50 1993, ICRU report 62 1999). Setup error can be measured by a 
comparison of megavoltage (MV) portal images, obtained from an EPID, with reference 
digitally reconstructed radiographs (DRRs) based on bony structures (Wong 1995, 
Herman 2001). The uncertainties caused by prostate motion are more complicated. 
Studies have shown that prostate motion can be up to a few centimeters from fraction-to-
fraction (Balter 1995, Crook 1995). Both inter-fraction and intra-fraction organ motion 
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can have a significant impact on treatment delivery if they are not accounted for. Prostate 
motion cannot be easily detected by use of an EPID because of the low soft-tissue 
contrast. Radiopaque markers implanted inside the prostate gland have been used to help 
localize the moving target by use of EPID (Litzenberg et al 2002, Herman et al 2003, 
Jiang et al 2007c). This is the technique used in this work. 
Advancements in linear accelerator (Linac) design, especially the introduction of 
kilovoltage X-ray tubes and flat-panel detectors make CBCT available at GRRCC 
recently. CBCT offers many opportunities for image-guided radiation therapy (IGRT). 
Jaffray (2002) surveyed 3 dimensional (3D) image-guided treatment systems and 
describes their early clinical experience. The importance of IGRT was emphasized by 
Millender and colleagues (2004) in a series of obese men with prostate cancer. Factors to 
compare correction technologies include accuracy, workload and patient tolerance etc. 
For example, online corrections may be preferred if they can be performed rapidly. The 
time required for measurement and correction can affect accuracy because of patient 
discomfort and internal organ motion. Large skin doses can occur with frequent 
kilovoltage image guidance in some circumstances. 
1.3.2   Data acquisition: DRR and electronic portal 
imaging device (EPID) 
In our study, patients were instructed to arrive for the planning CT one week after 
implantation with a full bladder and empty rectum. Three tattoos are then placed on the 
anterior, right and left lateral pelvis after the CT scan. On each treatment day patients are 
positioned using laser alignment to the marks on their skin, as well as the immobilization 
device. The therapist acquires one pair of orthogonal EPIs using the AP and LR setup 
fields and these constitute the comparison image set. Using both pairs of images, on-line 
repositioning of patients is accomplished through image matching using Varian Portal-
Vision software. A total of 4878 electronic portal images from 118 patients were acquired 
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over the course of the study. The data were used to analyze center of mass seed 
displacements relative to the isocenter. The daily on-line repositioning of the patients 
(calculation of the repositioning displacements) was accomplished through image 
matching using Varian Portal-Vision software. In order to study the displacement of bony 
anatomy relative to the isocenter and prostate relative to bony anatomy, an in-house built 
localization software (Proloc) was used to get the data of forty simulated DRRs and 1284 
EPIs for 20 prostate patients. The software is capable of determining mismatch between 
EPI and DRR using either seeds or bony anatomy. In ‘seed mode’ the three positions of 
the projected seeds are selected on both the DRR and the EPI and the software compares 
the selected positions on the EPI to the same positions on the DRR and then determines 
the required displacement in the anterior-posterior (AP), left-right (LR) and superior-
inferior (SI) directions. Using the same set of patient images and in ‘bony anatomy 
mode’, two reproducible bony anatomy pair points are selected on both the DRR and EPI. 
The software once again aligns the points on the two sets of images and determines the 
required displacement in the AP, LR and SI directions.  
1.3.3    Statistical analysis of IGRT image data 
High geometrical precision and accuracy is a prerequisite for a safe clinical application of 
conformal radiation therapy. Several factors contribute to the overall treatment accuracy. 
The error was used to describe any deviation between planned and delivered treatment. 
The statistical analysis of pool data for all the fractions of the patient group was use to 
obtain Gaussian PDF (GPDF) with mean and standard deviation (SD) (Rudat 1996). 
Another way to express error involves the group mean and SD of all patients’ means (van 
Herk 2004). For each patient, the mean and SD of the daily measurements are first 
obtained per patient. The group mean (Μ) is the mean of individual patients’ means; the 
SD of the individual patients’ means (Σ) and the root mean square (RMS) of the 
individual patients’ SDs (σ) were used to characterize the systematic error and random 
error. 
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As mentioned previously, a total of 4878 electronic portal images from 118 patients were 
extracted over the course of the study. The mean (M), standard deviation (Σ) and RMS 
(σ) of gold seed displacement relative to isocenter were studied and analyzed, which 
combined the setup error and organ motion. Data from the 20 patients were evaluated for 
setup error and prostate motion fraction-to-fraction simultaneously. Three data sets: seed 
displacement relative to beam isocenter, bony displacement relative to beam isocenter, 
and prostate displacement relative to bony anatomy, were analyzed and compared.    
1.4   IMRT Optimization and Dose 
Gradients 
1.4.1    Prostate IMRT protocol 
Dose escalation through 3D-CRT is widely recognized as an effective treatment approach 
in the management of prostate cancer. Improvements in local control have been shown 
when doses 76 Gy are applied (Lu 1995, Hanks 1998 1999 2000, Horwitz 2001, Zelefsky 
1998 2002a) compared to doses in the conventional range (70Gy). This benefit is 
particularly evident for patients with intermediate and high-risk prognostic factors, but 
has also been shown for patients with favorable prognostic factors (Vicini 2001, Zelefsky 
2002a). Late rectal toxicity with rectal bleeding is a well-known complication of high-
dose 3D-CRT (Hartford 1996, Michalski 2000, Skwarchuk 2000, Shu 2001, Chism 
2003). The biological mechanisms of radiation-induced damage are still not entirely 
understood and have been the topic of an extensive review (Denham 2002). Several 
reports have clearly indicated a significant dose–volume dependence of late rectal injury 
(the so-called volume effect) (Cheng 1999, Jackson 2001b, Wachter 2001, Fiorino 2002b, 
Huang 2002b, Chism 2003). 
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IMRT may prove efficacious by enabling consideration of dose escalation, by reducing 
margins and radiation exposure to dose-limiting normal tissues (Zelefsky 2002a, 2002b). 
IMRT offers a great flexibility to deliver dose to any desired volume. Organs at risk may 
potentially be effectively spared while still reaching high target dose coverage. However, 
it is difficult to exploit this flexibility when the margin is in the volume of intersection of 
PTV and OAR, such as the case of prostate. In order to keep rectal toxicity at acceptably 
low levels, knowledge of the dose volume relationship within a specific patient 
population must be acquired for a certain treatment setup, so that appropriate treatment 
constraints may be confidently applied (Lyman 1987, Kutcher 1996). DVHs have been 
used as an invaluable tool to evaluate the quality of a treatment plan. The DVH 
constraints for PTV and OAR in IMRT optimization are shown in Figure 1.6. The type 
includes: the minimum dose @ 100% volume DVH; maximum dose @ 0% volume 
DVH; minimum and maximum DVH applies to percentage volume of PTV and OAR. 
DVH data from these studies clearly indicate that the percent volume of rectum exposed 
to doses above 60–70 Gy plays a crucial role in determining radiation-induced rectal 
morbidity. It may also be expected that the anatomical definition of the rectum and 
variations in contouring may have a significant impact on the relationship between rectal 
DVH and late treatment morbidity (Fiorino 2002a). Although DVHs are important 
planning parameter and are linked TCP and NTCP, they do not contain spatial 
information about the dose distribution and are therefore not as effective as the dose 
gradient (Jiang et al 2007a). The convergence of the optimization algorithm will be 
determined by specific constraints in the objective function; however dose gradient is 
easier to interpret as a “limiting” parameter. Dose gradient analysis in this study is 
completely general and is independent of optimization algorithm. 
 




















Figure 1. 6: DVH constraints for PTV and OAR in IMRT for optimization. 
1.4.2 Dose gradients in IMRT dose distribution 
In practice, IMRT treatment planning is performed using a proprietary optimization 
algorithm and a custom optimization objective function including weighted dose 
constraints and DVH control points for the PTV and OARs. The DVH is a valuable tool 
for plan evaluation and optimization in the 3D treatment planning; also DVHs are linked 
to TCP and NTCP. However, the DVH curve cannot provide spatial dose information 
about the distribution of dose and are therefore not as effective as the dose gradient. For a 
given planning protocol, e.g. RTOG 0126 (Michalski 2004), the IMRT solutions from 
different institution and commercial treatment planning system will not be the same and 
it is therefore important to continue to specify the spatial dose distribution, including dose 
gradients as an indicator of how conformal the dose coverage actually is (Jiang et al 
2007a). The dose gradient is the rate change of dose profile along specific direction (the 
slope of the dose fall in that direction). Relating the targeting uncertainty to dosimetric 
variation depends on the gradients in the dose distribution produced in the patient; the 
most significant variations are at the periphery of the target volume. Novel beam delivery 
 
   27
systems allow highly conformal dose distributions to be produced within the patient. 
IMRT dose distributions are shaped to conform more closely to the PTV and avoid 
normal tissues, introducing large gradients at the boundary of PTV and normal structures. 
The steeper the dose gradients outside the PTV, the more sensitive the treatment will be 
to geometric uncertainties. The basic strategy is sketched in Figure 1.7. Differential dose 






Figure 1. 7: Tissue response for tumor and OAR. 
1.4.3   The impact of geometric uncertainties on dose 
gradients 
The effect of organ motion and positional uncertainties on the dose distribution can be 
estimated by convolving of the ‘static’ dose distribution initially obtained from the 
treatment planning system, with a PDF describing the geometric uncertainty of the 
anatomy. This approach was first proposed by Leong (1987) and subsequently applied by 
many investigators (Lind 1993, Rudat 1994 1996, Bel 1996, Keall 1999, Lujan 1999a 
1999b, Stroom 1999, Li 2000, McCarter 2000, McKenzie 2000a 2000b, van Herk 2000 
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2002, Booth 2001, O'Dell 2002, Jiang et al 2007a). Although the convolution method is a 
well-known and generally accepted method in radiation therapy, the limitations of a 
convolution method for modeling geometric uncertainties in radiation therapy must be 
noted (Craig 2003a, 2003b). Convolution requires several assumptions, this including 
that the patient is treated with an infinite number of fractions, each delivering an 
infinitesimally small dose; also convolution assumes shift invariance of the dose 
distribution, while internal inhomogeneities and surface curvature lead to violations of 
this assumption. Convolution can accurately estimate plan evaluation parameters for 
treatments of approximately 20 or greater fractions. In this study, the fraction numbers 
are over 30 fractions. The errors are largest near the surface due to the discontinuous 
nature of the dose distribution. In clinical examples, errors are small for a deep-seated 
tumor or critical organ, such as with prostate patients. Errors due to the presence of 
inhomogeneities appear negligible (Craig 2003a, 2003b). 
Most of the organ motion studies give the mean and standard deviation of motion in three 
orthogonal coordinate directions (Balter 1995, Crook 1995, Roeske 1995, van Herk 1995, 
Althof 1996, Beard 1996, Melian 1997, Dawson 1998, Zelefsky 1999). Doses at points 
along the anterior-posterior line through the isocenter were used to define the anterior and 
posterior doses for each patient, and the same method was used for the lateral and 
superior inferior directions. Geometric uncertainties can be incorporated in the treatment 
planning process provided that PDF of the geometric uncertainties can be estimated. In 
this work, dose gradients were obtained in the transverse and sagittal planes and analyzed 
to find the relationships between dose gradient and organ motion dose sensitivity 
(OMDS), TCP and NTCP. 
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1.5   Rectal DVH Control Points and Dose 
Gradient  
1.5.1    Prostate IMRT treatment planning 
IMRT Treatment plans were created for fifteen prostate patients and planned for supine 
patient treatment using a 6 MV photon beam from Varian 21EX linear accelerator 
(Varian Medical Systems, Palo Alto, CA). The prostate IMRT inverse treatment planning 
was optimized with a coplanar, isocentric five-field (5F: 0o, 72o, 144o, 216o, 288o) and 
seven-field (7F: 40o, 80o, 110o, 250o, 280o, 310o, 355o) techniques. An escalated 82 Gy 
prescription dose (2 Gy per fraction) was used for all IMRT plans. DVH control points 
for the PTV and OARs were adapted from RTOG 0126 (2004). The relative weights and 
DVH control points were adjusted for OARs for the IMRT plans. All patients were 
planned using the same objectives and constraints for PTVs and bladder but different for 
rectum as shown in Figure 1.8. Rectal DVH control points were lowered down as much 
as possible without compromising PTV. For each PTV, 3D uniform margins of 10 mm 
were used and compared with non-uniform margins of 5mm in posterior direction and 
10mm margins in other directions.  
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Figure 1. 8: Lowered rectal DVH control points in IMRT for optimization. 
1.5.2   Local maximum dose gradient (LMDG) 
The dose gradient is defined as the derivative of the dose profile along specific direction. 
The dose gradient used in this study is the absolute dose gradient (Gy/cm), and is 
determined at the isocenter along a specific direction in the sagittal plane in vicinity of 
posterior directions as shown in Figure 1.9. The magnitude of the dose gradient will tell 
how fast the dose falls in the specific direction. The local maximum dose gradient is the 
maximum dose gradient along the dose profile as shown in Figure 1.10, which was used 
to find the relationships with rectal dose, mean dose and NTCP. 
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Figure 1. 10: Maximum dose gradient along a dose profile. 
1.5.3    The impact of LMDG on NTCP 
The IMRT prostate treatment plan uses specific control points in the rectum and bladder 
DVH curves to set the treatment dose level (Yan 2000, Martinez 2001). The target dose is 
prescribed to meet the predetermined rectum and bladder constraints based on different 
dose volume limitations of rectum and bladder. A lack of knowledge about safe dose 
volume constraints may lead to inappropriate dose delivery with IMRT: excessively 
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cautious rectum sparing may increase the risk of missing the target, whereas the 
irradiation of large fractions of rectum may result in patients’ experiencing 
moderate/severe bleeding. A precise understanding of the tolerance of rectum in prostate 
treatment is essential because it determines the dose to the target. 
The relationships between rectal dose volume data and clinically observed rectal 
complications have been investigated and reported. However, few studies specify the 
spatial dose distribution, such as dose gradient as an indicator of how conformal the dose 
coverage actually is and its effect to the target and normal tissue (Jiang et al 2006a, 
2007a, 2007b). No one has previously focused on dose gradient as end points of 
commercial optimization protocols. For a given planning template, e.g. RTOG 0126 
(Michalski 2004), the IMRT solutions from different commercial planning system will 
not be the same and it is therefore important to specify the dose gradient as an indicator 
of how conformal the dose coverage actually is. Although DVHs are important planning 
parameter and are linked to TCP and NTCP, they do not contain spatial dose distribution 
information and are therefore hypothesized to be less effective than the dose gradient 
presented in this work.  
1.6   Cumulative Rectal Dose Considering 
Rectal Movement 
1.6.1    Rectal movement in AP direction 
Repeated portal images and gold seeds data were used to characterize daily prostate 
patient organ motion for 20 prostate patients (Jiang et al 2007c). The geometric 
uncertainties of prostate and rectum were assumed to be rigid body displacement; the 
calculation of rectal dose is based on a rigid-body model of localization uncertainty 
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involving translations of the prostate and rectum relative to a fixed dose distribution. The 
rectum was shifted in AP direction according to the prostate AP motion. IMRT plans for 
these 20 prostate patients were made with prescribed dose D = 78 Gy (2 Gy per fraction) 
using 15MV photon beam. PTV includes the prostate plus a 10 mm margin in the 
anterior, left-right, superior-inferior directions, and 7mm in posterior direction. The DVH 
of one fraction plan was obtained using the Pinnacle3 treatment planning system for five-
field (5F: 0°, 72°, 144°, 216°, 288°) and seven-field (7F: 40°, 80°, 110°, 250°, 280°, 310°, 
355°) IMRT. The possible rectal DVHs considering rectal movement in every fraction 
were used to calculate the rectal equivalent uniform dose in every fraction. 
1.6.2    Fractional EUD (EUDf) 
When considering non-uniform dose distributions, the DVH must be converted to an 
effective homogeneous dose to total volume as shown in Figure 1.11. The EUD 
algorithm uses the power-law relationship (Niemierko 1997), and the EUD in each 
fraction is called fractional equivalent uniform dose (EUDf) (Jiang et al 2006b). The 
EUDf for the rectum was calculated for each fraction according to the rectal AP 
movement over the course of treatment and used to calculate the NTCP for the rectum for 
the course of treatment. This model can produce the cumulative dose for the rectum 
incorporating motion, and the effect of the rectal motion on the cumulative rectal dose 
and risk can be assessed during the course of treatment.  
 






























Figure 1. 11: Rectal DVH and EUD. 
1.6.3  Evaluating rectal NTCP fraction-to-fraction 
DVH of the rectum is affected by a number of uncertainties and limitations; for example, 
the dose delivered to normal structure is conventionally assessed using dose distribution 
calculated from a single CT scan taken prior to the planning treatment scan. Complication 
arising from treatment is usually evaluated in terms of dose-volume histogram and 
NTCP. While dose distribution delivered to the rectum for prostate patient over the 
course of treatment is different from planned dose distribution because of the 
uncertainties such as patient setup error, rectal movement with respect to the bony 
anatomy, the delineation of the rectum, and the filling of rectum etc (Urie 1991, Webb 
1997, Fiorino 2002, Stasi 2006) and it is necessary to study the impact of organ motion 
on the rectal cumulative dose. 
Advanced planning and delivery techniques make dose escalation possible to spare 
normal tissues while maintaining target coverage. Dose escalation is further encouraged 
by the study results that higher target doses improve local control without increasing 
normal tissue toxicity (Zelefsky, 1998). However, the fluctuation of the internal organ 
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motion with respect to the bony anatomy fraction-to-fraction is associated with this multi-
fractional treatment. Rectal movement causes considerable dose uncertainty over the 
course of treatment and leads to the differences between planned dose distribution and 
the dose distribution that is actually delivered to the rectum. The most important 
limitation of analyzing dose to the rectum lies in the fact that the rectum moves during 
the course of treatment, both by distorting and by moving bodily (i.e. in the AP 
direction). 
Studies of patients with multiple CT scans taken during treatment for prostate cancer 
(Balter 1995, Mageras 1996, Melian 1997, Lebesque 1995, Roeske 1995, van Herk 1995) 
showed that the rectum can move 1 cm in the anterior-posterior direction with respect to 
the bony anatomy. Recently, ART using both online and offline correction schemes have 
been used for compensation of patient setup errors and organ motion (Lo¨f 1998, 
Yan1998). The calculation of dose is typically based on a rigid-body model of 
localization uncertainty involving translations (Killoran et al 1997) of the entire patient 
relative to a fixed dose distribution. Although the rectal movement is obvious for the 
rectum during a course of treatment for prostate cancer, it is not clear what kind of 
influences these variations might have on the predictive value of NTCP for the course of 
treatment. Few study reported the dosimetric consequences of the rectal movement. In 
this study, the rigid body model and serial portal imaging data were used to reproduce the 
cumulative dose distribution to the rectum considering internal organ motion using the 
fractional treatment plan method for prostate patients.  
The uncertainties of the internal organ motion result in variation of the delivered dose and 
can be evaluated fraction-to-fraction using EUDf. The rectal positional variations can be 
measured from portal imaging with gold seeds for prostate patients and expressed as 
EUDf deviations. This evaluation is performed by comparison of the dose-volume 
histogram per fraction, the rectal EUDf considering organ motion, and NTCP, with and 
without considering the internal organ motion. 
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Chapter 2 
IGRT Patient Study: Tracking 
Prostate Motion with Implanted 
Fiducials and MV EPI 
Minimization of setup errors and localization of the prostate within the patient are critical 
components of three-dimensional (3D) conformal radiation therapy (CRT) of prostate 
cancer with escalated dose. Setup error and organ motion were studied and analyzed for 
118 patients who were treated with image-guided radiation therapy (IGRT) using 
electronic portal image (EPI) and implanted three gold seeds within the prostate, in which 
20 patients were analyzed for setup error and prostate motion. Setup errors and gold seed 
displacements were determined from bony anatomy and gold seeds mismatch between 
the EPI and the simulation digitally reconstructed radiograph (DRR) respectively. 
Prostate motion relative to bony anatomy was determined by the difference between gold 
seed displacement and bony anatomy displacement. Daily on-line repositioning of 
patients was accomplished through image matching using Varian Portal-Vision software. 
The setup error and organ motion were compared fraction-to-fraction statistically. Image-
guided implanted gold seeds play a vital role in radiation therapy and will continue to be 
a reliable tool for prostate localization and minimization of setup errors. The reported 
positional variances are independent of treatment technique, and can be used to determine 
PTV margins using recipes reported in the literature. 
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2.1   Introduction 
Advances in radiation therapy technology enable higher precision treatments; however, 
as dose distributions become more conformal they may become more sensitive to 
treatment uncertainties, such as setup errors and organ motion. The developments in 
imaging modalities and computer algorithms have made quantitative measurements of 
treatment uncertainties possible, which have led to new strategies for reducing as well as 
incorporating uncertainties into the treatment planning process. The number of studies 
has increased significantly since the advent of electronic portal imaging device (EPID), 
which have become an important tool for studying setup error. Computed tomography 
(CT) scanners are also becoming commonplace, permitting studies of uncertainty in 
organ location based on repeat CT scans. Kilo-voltage or Mega-voltage cone beam 
computer tomography (CBCT) or kilo-voltage on-board imaging (OBI) systems are 
currently being employed for target volume localization. 
During treatment, the patient is aligned on a flat couch using the skin tattoos. The 
reproducibility of “virtual isocenter” is based on the agreement between the relative 
position of the anatomy at treatment and that of CT simulation. Daily alignment with 
lasers on external skin tattoos, and a weekly set of portal films for bony anatomy 
alignment has been a standard technique to reduce setup errors during radiation therapy. 
However, the outer patient skin markers are not accurate fiducial reference for internal 
structures, and hence more accurate position verification is based on internal fiducial 
markers. The use of radio-opaque gold seeds implanted in the prostate and visualized 
daily using EPIDs has therefore been employed to reduce both setup error and organ 
position variations and continue to provide accurate and efficient method for prostate 
localization (Wu et al 2001, Aubin et al 2004, Van den Heuvel et al 2006, Jiang et al 
2007c). 
Interest in setup errors and organ motion has grown quickly over the last decades, driven 
by medical needs and technological advances. Setup errors have been of continuing 
 
   38
interest in radiation oncology over the past decades (Alasti et al 2001, Nederveen et al 
2002, Rudat et al 1996). The number of setup studies has further increased significantly 
since the advent of EPIDs, which have become an important tool for studying setup error. 
Rational protocols that balance cost and efficacy have been developed to reduce and 
control setup errors (Kutcher et al 1995, Hurkmans et al 2001).  
Organ motion is inherently more difficult to correct than setup error. Organ motion refers 
to the variation of organ position and shape relative to the skeletal anatomy. During a 
single treatment, intra-fraction organ motion can be caused by breathing, heartbeat, 
swallowing, and peristaltic motion. Between treatments, inter-fraction organ motion may 
be caused by variable filling of the bladder and rectum, weight gain or loss, and other 
factors. The reported range of prostate motion varied significantly and comparison 
between studies is complicated due to different imaging procedures and tracking methods 
used by various researchers. Ten Haken et al (1991) have compared in 50 patients of CT-
based treatment plans and showed a range from 0 to 2 cm and an average of 0.5 cm of 
prostate movement, mostly in the anterior and/or superior direction. Melian et al (1997) 
performed four serial CT scans over a 5 ~ 6 week period on each of 12 patients. Target 
shifts of 0 to 3.0 cm in the anterior-posterior (AP) were observed and were correlated 
primarily with bladder filling. Forman et a1 (1993) examined patients who received CT 
scans on a weekly basis over the treatment course. An initial study of five patients 
showed an average prostate and seminal vesicle movement of 1.7 cm (range 0 to 3.5 cm), 
primarily in the AP direction. Beard et a1 (1996) examined movement of the prostate and 
seminal vesicles, for 12 patients who underwent two CT scans 4 weeks apart in the 
supine position. The greatest movement was observed in the AP direction, up to 1.6 cm 
with a median value of 0.45 cm, and appeared to correlate with bladder and rectal filling.  
There are large discrepancies in the reported results of prostate motion. Although some of 
the reported results are preliminary, there appears to be agreement that AP movement is 
more pronounced, and that movement correlates with bladder and rectal filling. There is 
clearly a need for additional studies with larger patient populations to better characterize 
organ motion and the influence of factors such as organ size and treatment technique. 
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The aim of this study is to analyze the interfraction setup error, gold seed displacement, 
and prostate motion for prostate patients, who were treated with IGRT at Grand River 
Regional Cancer Center (GRRCC), using three gold seeds implanted within the prostate 
and every day portal imaging. 118 prostate patients were analyzed for gold seed 
displacements relative to the isocenter, in which 20 patients were analyzed for setup error 
and prostate motion. Setup errors and gold seed displacement were determined from bony 
anatomy and gold seeds mismatch between the EPI and the DRR respectively. Prostate 
motion relative to bony anatomy was determined by the difference between gold seeds 
and bony anatomy displacement. Daily on-line repositioning of patients was 
accomplished through image matching using Varian Portal-Vision software.  Setup error, 
gold seed displacement and prostate motion among patients and fractions were compared 
and analyzed statistically.  
2.2   Methods and Materials 
2.2.1    Patients  
Patients with intermediate and low-risk prostate cancer were identified for radiation 
treatment in this clinical trial. IGRT plays an integral role in preparing these patients for 
accurate, reproducible treatments with daily online image verification. The eligibility 
criteria included clinical stage T1B, T1C and T2, N0, M0, a Gleason score less than 8 and 
prostate-specific antigen (PSA) levels less than or equal to 20. Three gold seeds were 
implanted in these patients trans-rectally in the prostate via a biopsy needle under 
ultrasound guidance. Gold seeds were cylindrical shape with 1.2 mm in diameter and 3 
mm in length (Northwest Medical Physics Equipment, a Med-Tec Company). This 
procedure assumes that the seeds are stable and do not move within the prostate (Pouliot 
2003).  
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2.2.2   CT planning and treatment planning 
The planning CT scan (Philips AcQsim CT, Philips Medical Systems, Cleveland Inc.) 
was acquired one week after implantation and treatment usually begins a few days later. 
Patients were instructed to arrive for the CT procedure with a full bladder (drinking 2 
glasses of water approximately one hour prior to the appointment) and with an empty 
rectum (asked to void before the appointment). Patients lie in a supine position on a solid 
flat carbon fiber couch top. An immobilization device is place below the knees. The 
pelvis area is scanned at increments of 3 mm. Three tattoos are then placed on the 
anterior, right and left lateral pelvis after the CT scan. All patients’ treatment planning 
was done using the pinnacle treatment planning system (Philips Pinnacle version 7.4 
TPS, Milpitas, CA) using 15MV photon beams. When the CT images have been imported 
into the treatment planning system, the prostate gland (clinical target volume (CTV)) was 
contoured by the radiation oncologist. The planning target volume (PTV) was created by 
expanding the CTV by 7 mm on the posterior direction and 10 mm in all other directions. 
The organs at risk (OAR) included the rectum, the bladder and femoral heads are also 
contoured. After the treatment planning one pair of orthogonal (AP and LR) DRRs are 
constructed in which the seeds and bony anatomy’s position can be located. This image 
set constitutes the reference image pair and are exported from the treatment planning 
system to the treatment software together with the patient treatment plan. 
2.2.3   Patient repositioning 
The patients are immobilized and treated in the supine position. On each treatment day 
patients are positioned using laser alignment to the skin tattoos and immobilization 
device. The therapist acquires one pair of orthogonal EPIs using the AP and LR setup 
fields and these constitute the comparison image set. The portal images are taken using 
Varian Oncology Systems a-Si flat panel electronic portal imager (Varian Medical 
Systems, Palo Alto, CA) mounted on a dual energy Linac 2100EX accelerator. The 
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imager has a sensitive area of 512 by 384 pixels with a pixel size of 0.784 mm. All 
images are acquired using about 3-4 MU of radiation exposure. Using both pairs of 
images, on-line repositioning of patients is accomplished through image matching using 
Varian Portal-Vision software. 
2.2.4   Data analysis 
Data from 118 patients were used to study gold seed displacements relative to the 
isocenter, in which 20 patients were used to study bony anatomy displacements relative 
to the isocenter and prostate motion relative to bony landmarks. Setup error is defined as 
the bony anatomy mismatch between the simulated DRR and the daily EPI. To quantify 
seed displacements, setup errors and prostate motion, statistical data such as the mean, 
standard deviations (SD) were calculated for the seeds, bony anatomy and prostate 
displacement. The quantification of these displacements was performed using the EPI 
obtained during treatment and the simulated DRR.  The images enabled us to detect the 
displacement of both bony anatomy and seeds. The displacement of both seeds and bony 
anatomy was calculated relative to an initial position, which is taken from the location of 
these internal structures as imaged during CT scanning. Comparing these structures on 
both the DRR and EPI requires that both images are represented in the same coordinate 
system and the projection of the isocenter of the treatment beam was chosen during 
treatment planning as the origin.  
Table 2.1 shows specification and computation of the group mean (M), the standard 
deviation of all the means (Σ) and the root mean square (RMS) (σ) of all the patients’ 
standard deviations. 
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Table 2.1: The group mean (Μ), the standard deviation of all the means (Σ) and the root 
mean square (RMS) (σ) of all the patients’ standard deviations. 
           
  Patient1 Patient2 Patient3 …     
Day1 D11 D21 D31 …   
Day2 D12 D22 D32 …   
Day3 D13 D23 D33 …   
… … … … …     
M = Group Mean  
Mean 1M  2M  3M  
… 
± Σ = SD   






The set-up error is the difference between the actual and intended position of the patient 
that is irradiated, with respect to the treatment beams during treatment. The intended or 
reference patient position is recorded on a reference image (DRR). On the reference 
image, anatomical structures, radio-opaque markers and the outline of the field which is 
used to generate the image are seen. The term match structure will be used when referring 
to the markers or structures which are used to match the treatment portal image with the 
reference image. In this paper, bony setup error or seed displacement is the difference 
between the measured position of a bony anatomy or seeds as defined by an EPID image 
and the reference position as defined by DRR respectively. Prostate displacement relative 
to bony anatomy is the difference between the seeds position relative to the isocenter and 
the bony anatomy position relative to the isocenter. For each patient, the mean and SD of 
the daily setup error, seed displacement or prostate displacement is the patient’s setup 
error, seed displacement or prostate motion respectively.  
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2.3   Data Collection and Analysis 
2.3.1     Seed displacements analysis: 118 patients 
Seed displacements relative to the isocenter combine both setup error and prostate 
motion. The pooled statistical data of the mean and standard deviation for seed 
displacements relative to the isocenter for all the fractions of 118 patients in AP, LR and 
SI directions are shown in Figure 2.1. In this study, the meaning of positive and negative 
in different direction is defined as following: the AP: Anterior (“-”), Posterior (“+”); LR: 
Left (“-”), Right (“+”); SI: Superior (“-”), Inferior (“+”). The frequency distribution of 
the seed displacement relative to the isocenter shows a normal distribution in all three 
directions. LR direction is narrow; AP and SI directions are much broader than LR 
direction; the predominant displacement was found in the posterior direction.  
 
Figure 2.1: Pooled statistical data of seed displacement relative to isocenter with mean 
(μ) and standard deviation (σ) in AP, LR and SI directions. 
 
Table 2.2 shows the group mean, standard deviation of all the means and RMS of SDs of 
all patients for the whole population. The data shows a preference of seed displacement 
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Table 2.2: Group mean (M) and standard deviation of all the means (Σ) and RMS (σ) of 
all SDs for seed displacements relative to the isocenter in a population of 118 patients in 
AP, LR and SI directions. 
AP LR SI
Mean (M) 2.05 -0.46 -0.97
SD (Σ) 2.65 1.74 1.86
RMS (σ) 3.16 1.91 2.10
4.12 2.58 2.81
Pooled (Seeds) 4.38 2.70 3.60
118 Patients Seed displacement: 1 SD (mm)
22 σ+Σ=tE
 
Seed displacement relative to isocenter distribution over the entire course of treatment 
(2439 fractions) for all 118 patients is shown in Figure 2.2. Figure 2.2a) gives the 
distribution in the AP direction, Figure 2.2b) in the LR direction and Figure 2.2c) in the 
SI directions. The predominant distributed points above zero in AP distribution indicate 
preference displacements in the posterior direction, the LR and SI distribution has equally 
distributed points above and below zero, indicating no preference displacements in LR 
and SI directions. The distribution does not narrow with treatment fraction, which means 
that the displacement persisted through out the entire course of treatment.  
The cumulative distribution of seed displacement relative to isocenter of the 118 patients 
in AP, LR and SI directions is shown in Figure 2.3. Figure 2.3a) is the distribution in the 
AP, LR and SI directions, whereas Figure 2.3b) is the distribution in the anterior, 
posterior, left, right, superior and inferior directions. The cumulative distribution of seed 
displacement was largest in the AP direction, and smallest in the LR direction. Most of 
the displacements in the AP direction were found to be in the posterior direction (74%) as 
opposed to 26% displacements in the anterior direction. In the AP direction, 49% of the 
displacements were smaller than 3mm, 38% within 3mm ~ 7mm, 10% within 7mm ~ 
10mm and 3% larger than 10mm; In the LR direction, 83.6% of the displacements were 
smaller than 3mm, 15% within 3mm ~ 7mm, 1% within 7mm ~ 10mm and 0.4% larger 
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than 10mm. In the SI direction, 70% of the displacements were smaller than 3mm, 25% 
within 3mm ~ 7mm, 4% within 7mm ~ 10mm and 1% larger than 10mm.  
The mean from individual patients as a function of SD for seed displacement relative to 
isocenter is shown in Figure 2.4. Figure 2.4a), 2.4b) and 2.4c) show the scatter plots in 
the AP direction (Pearson correlation coefficient r = - 0.22), LR: r = 0.05 and SI: r = 0.05, 
respectively. Most of patients means are positive (in the posterior direction, above the x-
axis) in figure 2.4a), and superior direction (below x-axis) in figure 2.4c). In the anterior 
and inferior direction, the weak tendency of large mean corresponding to large standard 
deviation was observed in figure 2.4a) and 2.4c). The dominant seed displacement in 
posterior and superior direction was also shown in the histograms of individual patient’s 
mean and SD of seed displacement relative to reference image for all the 118 patients in 
AP, LR and SI directions in Figure 2.5. The histograms of individual patient’s standard 
deviation shows the AP displacement is largest in this patient group. 
 
 
























































































Figure 2.2: Seed displacement relative to isocenter distributed over the entire course of 
treatment for all 118 patients; (a) AP (b) LR and (c) SI. 
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Figure 2.3: Cumulative frequency distribution of seed displacement relative to isocenter 
for 118 patients in AP, LR and SI directions; (a) AP, LR and SI directions (b) anterior, 
posterior, left, right, superior and inferior directions. 
 
 
























































Figure 2.4: Scatter plot of the mean from individual patients as a function of SD for seed 
displacement relative to isocenter for 118 patients; (a) AP: r = - 0.22 (b) LR: r = 0.05 and 
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Figure 2.5: The histograms of individual patient’s mean and SD of seed displacement 
relative to reference image for all the 118 patients in AP, LR and SI directions. 
2.3.2    Setup error analysis for 20 patients 
Some studies report setup errors measured after corrections are applied according to a 
protocol during the time the patients were treated (Hunt 1995, Hanley 1997). No data are 
given about the original setup errors. The data used in this study are the original setup 
errors before the corrections are applied. 
The pooled statistical data of the mean and standard deviation of setup error for 20 
patients in AP, LR and SI directions are shown in Figure 2.6. The frequency distribution 
of setup error shows a normal distribution in all three directions. LR direction is narrow; 
AP and SI directions are much broader than LR direction. The predominant displacement 
was found in posterior direction. 
The cumulative frequency distribution of setup error in three directions is shown in 
Figure 2.7. The cumulative distribution of setup error was smallest in the LR direction. 
88.3% of the setup errors were smaller than 3mm, 11.2% within 3mm ~ 7mm, and 0.5% 
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within 7mm ~ 10mm. In the AP direction, 68% of the setup errors were smaller than 
3mm, 28% within 3mm ~ 7mm, and 4% within 7mm ~ 10mm. In the SI direction, 78.1% 
of the displacements were smaller than 3mm, 18.8% within 3mm ~ 7mm, and 3.1% 
within 7mm ~ 10mm. The mean setup errors are 1.2 ± 3.3mm in AP, -0.1 ± 2.2mm in 
LR, -0.8 ± 2.9mm in SI. When separated into the various directions, the mean setup 
errors are 2.5 ± 2.2 anterior, 3.0±2.2 posterior, -2.5±2.0 superior, 2.2±1.6 inferior, 
1.7±1.3 left and 1.8±1.4 right.  
 
 
Figure 2.6: Pooled statistical data of setup error with mean and standard deviation in AP, 
LR and SI directions. 
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Figure 2.7: Cumulative frequency distribution of setup error for 20 patients in the AP, 
LR and SI directions; (a) AP, LR and SI directions (b) anterior, posterior, left, right, 
superior and inferior directions. 
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2.3.3    Prostate motion analysis for 20 patients 
The pooled statistical data of the mean and standard deviation of prostate motion for 20 
patients in AP, LR and SI directions are shown in Figure 2.8. The frequency distribution 
of organ motion shows a normal distribution in all three directions. LR direction is 
narrow; AP and SI directions are much broader than LR direction.  
 
Figure 2.8: Pooled statistical data of prostate motion with mean and standard deviation in 
AP, LR and SI directions. 
The cumulative frequency distribution of prostate motion in three directions is shown in 
Figure 2.9. The cumulative distribution of prostate motion was smallest in the LR 
direction with 96% of the organ motion smaller than 3mm, 4% within 3mm ~ 7mm. In 
the AP direction, 83.5% of the prostate motion was smaller than 3mm, 15.3% within 
3mm ~ 7mm, and 1.2% within 7mm ~ 10mm. In the SI direction, 75.9% of the 
displacements were smaller than 3mm, 20.6% within 3mm ~ 7mm, 3.1% within 7mm ~ 
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Figure 2.9: Cumulative frequency distribution of prostate motion relative to pelvis for 
the 20 patients in the AP, LR and SI directions; (a) AP, LR and SI directions (b) anterior, 
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2.3.4  Comparing setup error and organ motion for 20 
patients 
Table 2.3 shows the statistical data for setup error and prostate motion for 20 patients in 
three directions. For prostate motion, the mean is zero in the AP and LR directions, and -
0.2 mm in SI direction. There is no preference motion in three directions; while for setup 
error, dominant setup error was found in posterior direction and superior direction. There 
is larger setup error compared to organ motion in the AP directions. The observations are 
consistent with the findings of Alasti et al (2001). 
Table 2.3: M, Σ and σ for setup error and prostate motion for 20 patients in the AP, LR 
and SI directions. 
AP LR SI
Mean:M 1.20 -0.12 -0.82
SD (Σ) 2.17 1.35 2.55
RMS (σ) 2.62 1.78 1.64
3.40 2.23 3.03
Pooled (Bony) 3.33 2.20 2.93
Mean:M 0.00 -0.02 -0.16
SD (Σ) 1.36 1.05 2.44
RMS (σ) 2.22 0.91 1.95
2.60 1.39 3.12
Pooled (Prostate) 2.64 1.37 3.00
4.28 2.63 4.35
Pooled (Seeds) 4.18 2.40 3.61
Setup Error
Prostate Motion







Scatter plots of bone anatomy versus seed displacements for 20 patients are shown in 
Figure 2.10. All displacements are relative to the isocenter. The x-axis depicts 
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displacements of seed displacement relative to isocenter, whereas the y-axis shows bony 
displacement relative to isocenter. Figures 2.10a), 2.10b) and 2.10c) show the scatters of 
the displacements for all fraction in AP, LR and SI directions respectively. Figures 2.10d) 
and 2.10e) show the individual patient mean and SD in AP, LR and SI directions. The 
correlation between seed displacements and bony anatomy is highest in the LR direction 
(Pearson’s correlation coefficient r = 0.83). In the AP direction the correlation coefficient 
(r = 0.78) is smaller compared to the LR direction and the correlation coefficient (r = 
0.58) is lowest in the SI direction. Nederveen’s et al (2002) reported correlation 
coefficient between seed and bone displacements of 0.71 in the AP direction, 0.92 in the 
LR direction, and 0.46 in the SI direction. The correlation coefficient of mean between 
bony landmark and seed displacements are 0.87 in AP, 0.76 in LR and 0.56 in SI. 
Nederveen et al (2002) reported a correlation coefficient of 0.86 in AP, 0.91 in LR, and 
0.08 in SI direction. A similar correlation for the SD revealed correlation coefficients of 
0.83, 0.92, and 0.55 in AP, LR and SI directions, respectively. 
The organ motion and setup error from the 20 patient studies are shown in Figure 2.11. 
The error bars indicate one standard deviation. The mean of AP, LR and SI prostate 
motion and setup error for the 20 patients was calculated by averaging all displacements 
over all fractions for each patient. The mean of prostate motion varied from –3.2 to 
2.4mm in AP, -1.7 to 3.4mm in LR, -4.4 to 7.2mm in SI, with SD changing from1.2 to 
3.3mm in AP, 0.4 to 1.5mm in LR, 1.2 to 2.4mm in SI directions respectively. While the 
mean of setup error varied from –3.6 to 4.4mm in AP, -2.2 to 2.3mm in LR and –7.6 to 
3.7mm in SI, with SD changing from 1.2 to 4.8mm in AP, 0.6 to 2.5mm in LR, 1.0 to 
2.6mm in SI directions respectively. The setup errors in the AP direction were larger in 
magnitude than those in the SI and LR directions, while the setup error in the LR 
direction was smallest. The dominant setup errors were found in the posterior direction 
and superior direction for the AP and SI setup errors respectively.  
A comparison of cumulative frequency distribution of prostate motion and setup error for 
20 patients in the anterior, posterior, left, right, superior and inferior directions is shown 
in Figure 2.12. There is larger setup errors compared to organ motion in the posterior and 
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superior directions, while larger prostate motion compared to setup error was found in the 
anterior and inferior directions. Alasti et al (2001) reported larger prostate motion 
compared to the setup errors in both AP and SI directions. A little bit difference was 
found in LR direction for both setup error and organ motion. 
Scatter plots of prostate motion versus setup error are shown in Figure 2.13. The mean of 
prostate motion versus setup error for every patient in the AP, LR and SI directions are 
shown in Figure 2.13 (d); and the SD of prostate motion versus setup error in the AP, LR 
and SI directions are shown in Figure 2.13 (e). There is no correlation between prostate 
motion and bony shift. Prostate motions relative to bone, and bone displacements relative 
to isocenter as function of treatment number also showed that prostate motion is 
independent to bony shift in Figure 2.14. 
The resultant displacement was obtained by adding three displacements in quadrature: 
222 SILRAPR ++= . The resultant displacement for seed displacements relative to 
isocenter, setup error and prostate motion for the pooled data of 20 patients are shown in 
Figure 2.15. If corrections were applied with resultant displacement bigger than 5 mm, 
for tracking the seeds from localization of fiducial markers, 61% of the fractions have 
resultant displacement larger than 5mm in the 20 patient groups; while for localization of 
bony landmarks alone, 37% of fractions are displaced by more than 5mm. For internal 
organ motion relative to bony anatomy, 23% of the fractions have displacement larger 
than 5mm. The just use of daily EPI alignment of bony anatomy would still result in 23% 
of fractions larger than 5mm because of internal organ motion.  
 






















































































































Figure 2. 10: Scatter plots of bony landmark versus seed displacement relative to 
isocenter. (a) AP: r = 0.78 (b) LR: r = 0.83 (c) SI: r = 0.59 (d) The mean of 20 patients in 
the AP, LR and SI directions: r = 0.87, 0.76, 0.60 in AP, LR and SI directions, 





































































Figure 2.11: Prostate motion and setup error and for the 20 patients in the AP, LR and 















0 2 4 6 8 10 12


































0 2 4 6 8 10 12


































0 2 4 6 8 10 12



























Figure 2.12: A comparison of cumulative frequency distribution of prostate motion and 
setup for 20 selected patients. (a) Anterior and Posterior directions (b) Left and Right 























































































































Figure 2. 13: : Scatter plots of prostate motion versus setup error (a) AP: r = -0.03 (b) 
LR: r = -0.16 (c) SI: r = -0.27 (d) The mean of prostate motion versus setup error for 20 
patients in the AP, LR and SI directions: r = 0.15, -0.12, -0.34 in AP, LR and SI 
directions, respectively (e) SD of prostate motion versus setup error in the AP, LR and SI 







































































































































































































































Figure 2.14: Prostate motion relative to bone, and bone displacement relative to isocenter 





























































































































































































































Figure 2.14: Prostate motion relative to bone, and bone displacement relative to isocenter 





























































































































































































































Figure 2.14: Prostate motion relative to bone, and bone displacement relative to isocenter 






















































































































































































































Figure 2.14: Prostate motion relative to bone, and bone displacement relative to isocenter 









Figure 2.15: The resultant 222 SILRAPR ++=  for seed displacements relative to 
isocenter, setup error, and prostate motion for the pooled data of 20 patients. 
 
2.3.5    The effect of body size on setup error 
The predominance of setup error in the anterior-posterior direction found in the study 
may be mainly due to the use of skin markers to determine the isocenter height in 
combination with the use of the pelvic bones as a match structure. The movement of the 
skin markers used for patient positioning relative to the pelvic bones, results in a setup 
error. The skin movement might be due to respiration, weight loss, patient’s relaxation or 
body size. This movement is expected to be small in the LR and SI directions and more 
pronounced in the AP direction. The correlation of body size and setup error was 
analyzed. The body size was characterized by the maximum separation in AP direction. 
The mean, SD and AP setup error (defined as absolute mean plus two SDs) for AP setup 
error with the relationships of body size for 20 patients are shown in Figure 2.16. The 
mean of AP setup errors were divided into two parts by x-axis, for most of the patients, 
the means of setup error are positive (above the x-axis in posterior direction), the 
correlation coefficient is 0.27, while for the patients with negative means (below the x-
axis in anterior direction), the correlation coefficient is - 0.46 as shown in Figure 2.16 a). 
The correlation coefficient between body sizes and SD is 0.43 in Figure 2.16 b); however 
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is 0.51. For the 10 patients with large setup errors in this 20 patients group, the 
correlation coefficient between the AP setup error and AP separation is 0.82 as shown in 
figure 2.16 d). There is the tendency that the larger body size leads to larger AP setup 
error. This result is consistent with Luchka (1997)’s study, who reported setup errors for 
























































































Figure 2.16: The mean, SD and AP setup error (absolute mean plus two SDs) versus AP 
separation for 20 patients (a) mean (b) SD: r = 0.43 (c) mean plus two SDs: r = 0.51 (d) 
10 patients with larger AP separation: r = 0.82. 
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2.3.6   The effect of bladder and rectal volumes on 
prostate motion 
The relationships of the mean of prostate AP motion with bladder volume and rectal 
volume are shown in Figure 2.17. The correlation coefficient of the mean of prostate AP 
motion with bladder volume is - 0.34. There is the tendency that the mean of AP motion 
is in anterior direction (negative) for larger bladder. The largest bladder volume (patient 
6, bladder volume: 578.16 cm3) results in the most of the motion in anterior direction 
(Mean = -3.15mm), which may be the reason that the bladder volume reached the 
maximum capacity during the CT scanning and relative smaller for the course of 
treatment comparing to the planning bladder volume. The correlation coefficient of the 
mean of prostate AP motion with rectal volume is 0.35. The tendency is opposite to the 
relationship between AP motion and bladder volume because the opposite position the 



















































Figure 2.17: The mean of prostate AP motion versus volume (a) bladder: r = -0.34 and 
(b) rectum: r = 0.35. 
(a) (b) 
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The relationships of the mean of prostate AP motion with bladder volume and rectal 
volume for the AP motion bigger than 5mm are shown in the Figure 2.18. The correlation 
coefficient of the mean of prostate AP motion with bladder volume is -0.47, while the 



















































Figure 2.18: The mean of prostate AP motion versus volume for the AP motion bigger 
than 5mm (absolute mean plus two SDs) (a) bladder: r = -0.47 and (b) rectum: r = 0.44. 
The relationships of the SD of prostate AP motion with bladder volume and rectal 
volume for the AP motion bigger than 5mm are shown in the Figure 2.19. The correlation 
coefficient of the SD of prostate AP motion with bladder volume is -0.67. The bladder 
was asked to be full during CT scan and everyday treatment. The smallest bladder has the 
largest SD (Patient 2, Bladder volume = 85.82 cm3, SD = 3.28 mm). SD decreased with 
increasing bladder volume, however the SD increase again when bladder is too full. The 
correlation coefficient of the mean of prostate AP motion with rectal volume is 0.60. 
During CT scan and everyday treatment, the rectum should be emptied. The SD increased 
with increasing rectal volume.  
(a) (b) 
 












































Figure 2.19: SD of prostate AP motion versus volume for AP motion bigger than 5mm 
(absolute mean plus two SDs) (a) bladder: r = -0.67 and (b) rectum: r = 0.60. 
Figure 2.20 shows the relationships of the prostate AP motion (defined as absolute mean 
plus two SDs) with bladder volume and rectal volume for the AP motion bigger than 
5mm. Except patient 7 (Bladder volume = 278.88 cm3, Rectal volume = 83.44 cm3, AP 
motion = 7.74 mm), the rest of patients show that too smaller or larger bladder volume 
will result in the larger AP motion because of the bigger bladder volume variation 
between the planning CT scan and everyday treatment. Same result was found in Figure 














































Figure 2.20: Prostate AP motion (absolute mean plus two SDs) versus volume for AP 
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There is no obvious correlation between the prostate motion and prostate volume, also no 
obvious correlation between the prostate motion and maximum AP separation of the body 












































Figure 2.21: Prostate motion (R = 222 SILRAP ++ ) versus volume (a) prostate (b) 
maximum AP separation of the body. 
2.3.7  Comparing the results with other researchers 
The setup errors (1 SD) in this study compared with other researchers in the literature are 
shown in Table 2.4, and range from 1.8 to 7.3 mm in AP direction, 1.4 to 8.8 mm in SI 
direction, lateral direction is smallest.  
Hanley et al (1997) did a retrospective analyzes of port films of 50 patients. Patient 
positioning uncertainty was determined using port film from three projections: two 
oblique, and one lateral. A total of 1239 port films and 300 simulator films were analyzed 
for the study. The distribution of setup errors for the population of patients were 1.9 mm, 
2.0 mm and 1.7 mm, in the AP, LR and SI directions, respectively. Alasti et al (2001) 
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also analyzed a total of 2549 portal images from 33 patients. Data from 23 patients were 
analyzed for setup errors and 10 were analyzed for prostate motion. Setup errors were 
characterized by standard deviations of 1.8 mm in AP and 1.4 mm in SI directions. The 
setup errors in our research are found to be predominant in the AP direction. This agrees 
with the work by Dunscombe et al (1993 ), Hunt et al (1995), and Alasti et al (2001) who 
showed similar largest displacement in the AP direction and least in the LR direction; 
however the researches from Althof et al (1996), Rudat et al (1996), van Herk et al 
(2004) showed the largest displacement in the SI direction. The uncertainties of the skin 
markers used for patient positioning relative to the pelvic bones result in setup error. The 
skin markers’ variation might be due to respiration, weight loss, patient’s relaxation or 
body size. This movement is expected to be small in the LR and SI direction and more 
pronounced in the AP direction.  
The prostate displacement occurs independently from the bony anatomy and compared 
results are shown in Table 2.5. The repositioning the patient using bony anatomy only 
slightly contributes to a better target positioning. The range of prostate motion was 
different from different researchers and the comparison among studies is complicated due 
to different procedures employed by different researchers. Organ motion was reported to 
be the result of pressure from bowel gas and the filling of rectum and bladders (Roeske et 
al 1995, Melian et al 1997). Additionally, the high variability was noted in many of the 
studies because of different patient population sizes, different bladder sizes (full vs. 
empty), and different number of measurements, methods of measurements, and time 
interval between measurements (Balter et al 1995, Roeske et al 1995, van Herk et al 
1995, Melian et al 1997, Vigneault et al 1997, Alasti et al 2001, Wu et al 2001). Melian 
et al (1997) studied the variation of bladder and rectum filling in 12 patients and found 0 
~ 3.0 cm AP shifts, correlated with filling. Balter et al (1995) used weekly orthogonal 
radiographs to measure prostate motion and observed translational of a maximum of 
7.5mm with typical range between 0 ~ 4 mm, predominantly in AP and SI direction. In 
agreement with their results, our results show the largest motion in the AP direction and 
the smallest motion in the LR direction; and too smaller or larger bladder volume will 
result in the larger AP motion because of the bladder volume inconsistency between the 
planning CT scan and everyday treatment. 
 
   72
 
Table 2.4: Setup error specified as one standard deviation (mm) in the AP, LR and SI 
directions. 
       
Setup Error (1 SD) (mm) AP LR SI 
Results from this study 3.3 2.2 2.9 
Alasti et al (2001) 1.8 - 1.4 
Althof et al (1996) 2.4 3.1 3.2 
Antolak et al (1998) 5.1 4.0 2.3 
Dong (1995) 2.3 2.7 2.1 
Dunscombe et al (1993) 5.2 4.0 4.1 
Hanley et al (1997) 1.9 2.0 1.7 
Hunt et al, EPID (1995) 5.3 5.5 5.3 
Hunt et al, film (1995) 7.3 5.2 5.3 
Jones et al (1995) 3.1 2.5 2.2 
Rudat et al (1996) 4.9 3.1 5.4 
Tinger et al (1998) 3 3.1 2.1 
van Herk et al (2004) 2.3 3.9 8.8 
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Table 2.5: Prostate motion specified as one standard deviation (mm) in the AP, LR and 
SI directions. 
        
Prostate Motion (1 SD) (mm) AP LR SI 
Results from this study, seeds 2.6 1.4 3.0 
Alasti et al, seeds (2001) 5.8 - 3.3 
Althof et al, seeds (1996) 1.5 0.8 1.7 
Antolak et al, CT (1998) 3.6 0.7 3.6 
Balter et al, seeds (1995) 2.3 0.9 1.9 
Crook et al, seeds (1995) 4.1 1.5 5.0 
Litzenberg et al, CT (2002) 2.4 1.9 2.1 
Melian et al, CT (1997) 4.0 1.2 3.1 
Roeske et al, CT (1995) 3.9 0.7 3.2 
Rudat et al, CT (1996) 3.7 1.9 - 
Schiffner et al, CT (2007) 2.1 0.9 2.4 
Tinger et al, CT (1998) 2.6 0.9 3.9 
Van Herk et al, CT (1995) 3.8 1.3 2.4 
Vigneault et al, seeds (1997) 3.5 1.9 3.6 
Wu et al, seeds (2001) 2.3 - 2.1 
 
2.4   Chapter Summary 
Daily electronic portal images with gold seeds provided an effective way to verify and 
correct the position of targets immediately prior to radiation delivery. There is a direct 
correlation of patient size and magnitude of setup error where, the larger a patients body, 
the larger the potential setup error. Prostate motion occurred independently from bony 
anatomy displacement during treatment, and correlated with bladder and rectal filling. 
Margins, though reduced in size after correcting setup error by bony anatomy based 
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position verification, are still needed to account for internal organ motion. If corrections 
were applied with resultant displacement bigger than 5 mm, for tracking the seeds from 
localization of fiducial markers, 61% of the fractions have resultant displacement larger 
than 5 mm in the 20 patient groups; while for localization of bony landmarks alone, 37% 
of fractions are displaced by more than 5 mm. For internal organ motion relative to bony 
anatomy, 23% of the fractions have displacement larger than 5 mm. The use of daily EPI 
alignment of bony anatomy would still result in 23% of fractions larger than 5 mm 
because of internal organ motion. The margin is determined according to the specific 
setup technique: for a conventional beam setup without image guidance, both setup error 
and organ motion should be considered; for correction of daily bony setup error by EPID, 
a margin should be considered to account for internal organ motion; for correction of 
fiducial markers, a margin is still needed to account for intra-fraction organ motion 
during treatment and other uncertainties. Margin is also determined by treatment 
techniques: for a four-beam box, 95% coverage is required according to the ICRU-62 
(ICRU 1999) report; for IMRT with correction of inter-fraction tumor motion, 4 mm 
margin should be used for intra-fraction motion and other uncertainties because of high 
dose gradient. Significant reduction in both setup error and organ motion can be achieved 
by on-line target-based position verification using gold seeds image-based verification or 
recently employed cone beam CT. The dosimetric effects of organ motion on the rectum 
were quantified in other chapter. 
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Chapter 3 
 
The Effect of Organ Motion in a 
Region of High Dose Gradient 
The aim in this chapter was to investigate the effects of geometric uncertainties on 
intensity-modulated radiation therapy (IMRT) treatment planning of prostate patients 
using dose gradients and probability density function (PDF) of geometric uncertainties. 
Spatial dose distributions were generated from a Pinnacle3 planning system using a co-
planar, five-field IMRT technique. Five types of beam plans were created for each patient 
using equally spaced beams but shifting the angular displacement of the beam set by 15o. 
Dose profiles taken through the isocenter in anterior-posterior (AP), left-right (LR) and 
superior-inferior (SI) directions for IMRT plans were analyzed by exporting RTOG file 
data from Pinnacle. The convolution of the “static” dose distribution D0(x,y,z) and 
Gaussian PDF, denoted as P(x,y,z), was used to analyze the combined effect of 
repositioning error and internal organ motion. The percentage mean dose deviation 
(PMDD) was defined as dose difference between the mean dose (MD) of the blurred dose 
profile from isocenter to the edge of PTV and the mean dose of the whole planning target 
volume (PTV). The PMDD depended on the dose gradient and organ motion PDF. Organ 
motion dose sensitivity (OMDS) was defined by the rate of change in PMDD with 
standard deviation (SD) of Gaussian PDF and was found to increase with the maximum 
dose gradient in anterior, posterior, left and right directions. Due to common inferior and 
superior field borders of the field segments, the sharpest dose gradient occurred in the 
inferior or both superior and inferior directions. Thus, prostate motion in the SI direction 
produced the greatest dose difference. The PMDD is within 2.5% when SD is less than 
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5mm, but the PMDD is over 2.5% in inferior direction when SD is higher than 5 mm in 
inferior direction. Verification of prostate organ motion in the inferior directions is 
essential. The margin of the PTV significantly impacts on the confidence of tumour 
control probability (TCP) and level of normal tissue complication probability (NTCP). 
Smaller margins help to reduce the dose to normal tissues, but may compromise the dose 
coverage of the PTV. Lower rectal NTCP can be achieved by either smaller margin or 
steeper dose gradient between PTV and rectum. With the same dose volume histogram 
(DVH) control points, the rectum had lower complication in the seven-field technique 
because of the steeper dose gradient between the target volume and rectum. The 
relationship between dose gradient and rectal complication can be used to evaluate IMRT 
treatment planning. The dose gradient analysis is a useful tool to evaluate IMRT 
treatment plan and can be used for QA checking of treatment plan for prostate patients. 
3.1   Introduction 
In conformal radiation therapy (CRT) and IMRT, the organ motion and positional 
uncertainty of the clinical target volume (CTV) is managed by adding margins to form a 
PTV to ensure the desired tumor dose coverage (ICRU report 50 1993, ICRU report 62 
1999). This approach generally leads to increased NTCP. The use of IMRT is increasing 
rapidly due to promising clinical outcomes (Webb 1993, 1997, 2000, 2004, 2006, IMRT 
group 2001, Palta and Mackie 2003). IMRT provides more degrees of freedom for 
shaping dose distribution to produce highly conformal dose coverage of PTV and 
significantly reducing the dose to adjacent organ at risk (OAR). However, as the dose 
gradient at outside edge of PTV increases, the impact of setup error and internal organ 
motion uncertainties will be much higher.  
Some specific studies in organ motion are highlighted: Mageras et al (1996) randomly 
sampled organ motions from a database of serial CT images previously acquired over the 
course of radiation therapy for a population of patients; these motions are then mapped 
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onto the patient being planned. Yan et al (1999) retrospectively reconstructed the dose 
delivered to the patient during the initial treatment fractions by acquiring multiple on-line 
CT images. Fontenla et al (2001a, 2001b) proposed a model for incorporating the effects 
of organ motion into the calculation of dose in a statistical fashion based on serial 
imaging measurements of organ motion. In Craig’s study (2003c, 2005); impact of 
geometric uncertainties on treatment techniques was evaluated for prostate cancer. Schaly 
et al (2004, 2005a, 2005b) used a dose warping technique to assess the impact of image-
guided radiation therapy (IGRT) strategies that correct patient setup errors and inter-
fraction organ motion. However, no one has previously focused on absolute dose 
gradients as optimization parameters of commercial optimization algorithms and few 
studies gave the quantification relationship between the effects of organ motion on dose 
gradients. In this study, the effects of dose gradient along the anterior-posterior, superior-
inferior and left-right directions of internal organ motion were analyzed and quantified 
for the first time. 
Although DVHs are important planning parameter and are linked to TCP and NTCP, they 
do not contain spatial information about the distribution of dose and are therefore not as 
effective as the dose gradient. The dose gradient is the rate change of dose profile along 
specific direction (the slope of the dose fall in that direction). Complete dose profile is 
required to assess impact for internal organ motion. The maximum dose gradient is the 
steepest part of the dose profile at outside edge of PTV and produces the largest effect on 
the target dose for the internal organ motion.  
To assess the impact of patient repositioning and internal organ motion on IMRT 
treatment plans, a dose gradient analysis is performed on spatial dose profile through the 
dose distribution (i.e. a linear voxel sequence). Dose gradient analysis is completely 
general and is independent of optimization algorithm. The method in this study can be 
easily adapted to arbitrary internal organ motion. Fundamental to this technique is 
directional gradient and probabilistic (density function) characterization of motion and 
determination of the blurred dose gradients along directions relevant to the motion. The 
analysis of the dose gradient is a powerful tool to evaluate IMRT treatment plan in light 
of geometric uncertainty.  
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3.2  Methods and Materials 
3.2.1   Patient and treatment planning data 
In this study, IMRT Treatment plans are created for fifteen prostate patients, covering a 
range of prostate target volumes from 17.3 cm3 to 87.1 cm3, and different overlap of PTV 
with rectum and bladder. The prostate, seminal vesicles, bladder, rectum, and femoral 
heads of the prostate patients were contoured by the therapist using CT data. Two PTVs 
for each patient are generated: PTV1 includes the prostate and seminal vesicles plus a 10 
mm margin; PTV2 includes the prostate only plus 10 mm margin. For each PTV, 3D 
uniform margins of 2, 5, 8, and 10 mm were used.  
3.2.2   IMRT treatment planning and objective 
functions 
All cases were planned for supine patient treatment using a 6 MV photon beam from 
Varian 21EX linear accelerator (Varian Medical Systems, Palo Alto, CA). All were 
devised for coplanar treatment with the long axis of the patient couch parallel to the axis 
of the treatment machine gantry rotation. Plans were produced for each patient using 
equally spaced beams but shifting the angular displacement of the beam set by 15o. The 
prostate IMRT inverse treatment planning was optimized with a coplanar, isocentric five-
field technique, involving five plans with different beam angles as shown in Table 3.1. 
Five and seven coplanar beams were used for comparison.  
An escalated dose of 82 Gy in 2 Gy per fraction was prescribed for all IMRT plans. The 
DVH control points for the PTV and OAR were adapted from RTOG 0126 (Michalski 
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2004). The minimum and maximum dose to the target and maximum dose to the OARs 
are parameters in the optimization cost function, DVH control points and the weights are 
specified for the PTV and OAR. The weights and DVH control points of the PTV and 
OAR were adjusted and changed to satisfy the RTOG guideline for IMRT plans. All 
patients were planned using the same objectives and constraints. A 3D dose distribution 
was calculated using the Pinnacle inverse treatment planning system (Pinnacle 2001, 
2002).  
Table 3. 1: Gantry angles for 5 coplanar and 7 coplanar plans. 
Plan Gantry angle ( o ) 
5 coplanar               
plan1 0 72 144 216 288   
plan2 15 87 159 231 303   
plan3 30 102 174 246 318   
plan4 45 117 189 261 333   
plan5 60 132 204 276 348   
 coplanar        
5B_1 0 72 144 216 288   
5B_2 35 110 180 250 325   
7 coplanar        
7B_1 0 51 102 153 204 255 306 
7B_2 40 80 110 250 280 310 355 
 
3.2.3   TCP and NTCP 







=                                                        (3.1) 
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where D is dose, a and b are related to D50 and γ50. Okunieff et al (1995) summarized 
clinical data for a variety of tumors and reported parameters that can be related to slope 
and dose to control 50% of tumors. The multi-institutional data for the tumor control 
grades T2–T4 were used (for grade T4: TD50 = 41.78Gy and γ50 = 0.66, for grade T3: 
TD50 = 46.29Gy and γ50 = 0.42, for grade T2: TD50 = 45.18Gy and γ50 = 0.34), where TD50 
(Gy) and γ50 (%%) are the dose and normalized slope at the point of 50% probability 
control. 
NTCP is calculated using the Lyman-Burman-Kutcher algorithm (Lyman 1985, Burman 

















vTDDt −=                                                                   (3.3) 
where ν=V/Vref and TD50(ν)=TD50(1)ν-n , as suggested by Burman et al. (1991), TD50 of 
80 Gy, n of 0.12, and m of 0.15 were use for rectum. 
 
3.2.4   Convolution of dose gradient with geometric 
uncertainty 
In this paper, the static dose distribution D0 is convolved with a PDF describing the 
geometric uncertainty P. The result is the blurred dose distribution that is expected to be 
delivered in the presence of this uncertainty. 
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∫∫∫ −−−== ''')',','()',','(),,()( 0 dzdydxzyxPzzyyxxDzyxDrD
v
                  (3.4) 
where x, y, and z refer to coordinates in the left-right (LR), anterior-posterior (AP), and 
superior-inferior (SI) directions, respectively. The dose profiles are determined across the 
isocenter in the LR, AP and SI directions by exporting RTOG files from Pinnacle and 
analyzed by MATLAB.  
For simplicity, equation (3.4) is denoted as: 
')'()'()(
0
rdrPrrDrD vvvvv −= ∫∫∫                                         (3.5) 
Taking the derivative is well defined by convolution (Arfken 1995), 
')'()'()(
0
rdrPrrDrD vvvvv −∇=∇ ∫∫∫                                     (3.6) 
where rv is the vector, denotes x, y and z. The term )(0 rD
v∇  is the static dose gradient 
G0; )(rD
v∇  is the blurred dose gradient G; P is the PDF (motion kernel). The simplified 
form can be expressed: 
PDD ⊗∇=∇ 0                                                       (3.7) 
where ⊗ denotes the convolution operator, given a reference point 3Ra ∈v ; the blurred 
dose can be expressed as: 
[ ]∫∫ ⊗∇+=∇+= CC rdPDaDrdrDaDrD
vvvvvv
0)()()()(                  (3.8) 
Where C is the line from av to rv ; same methodology can also be applied for the 
derivative of motion kernel: 
')'()'()(
0
rdrrPrDrD vvvvv −= ∫∫∫                                         (3.9) 
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PDD ∇⊗=∇ 0                                                       (3.10) 
[ ]∫∫ ∇⊗+=∇+= CC rdPDaDrdrDaDrD
vvvvvv
0)()()()(                  (3.11) 
By integrating equation (3.7), the blurred dose including organ motion was obtained in 
equation (3.8), which explicitly identifies the fundamental components influencing the 
blurred dose which are dose gradient and motion kernel. The static dose profile and dose 
gradient are shown in Figure 3.1; and the Gaussian PDF with SD and derivative of PDF 
are shown in Figure 3.2. The blurred dose can be expressed by the integration of either 
the static dose gradient convolved with the PDF as shown in Figure 3.3 or the integration 
of the static dose convolved with the derivative of the PDF as shown in Figure 3.4. That 
is, the blurred dose gradient can be determined from the convolution of the static dose 
gradient with PDF in Figure 3.3 or determined from the convolution of the static dose 
with derivative of PDF in Figure 3.4. For the section of the profile where the dose 
gradient is near zero (inside the PTV), there will be minimal impact on the blurred dose 
for the internal organ motion, while for the section of the profile at outside edge of PTV 
where the dose gradient is the steepest, there will be maximal impact for internal organ 
motion. The contribution of the convolution of static dose with the derivative of PDF will 
have maximal impact on the blurred dose when the dose changes sharply outside edge of 
PTV. The algorithm used in Figure 3.4 is the edge detection used in imaging process. The 
blurred dose profile inclusion of geometric uncertainties can be obtained by integration of 
blurred dose gradient as shown in Figure 3.3 and Figure 3.4. The steps used in calculating 
blurred dose distribution including geometric uncertainties are shown in Figure 3.5. 
 




































































































∫ Integration of 
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gradient 



















































Figure 3. 3: The blurred dose gradient (c) is determined from the convolution of the static
dose gradient (a) with PDF (b). The blurred dose including geometric uncertainties (d) is 



























































∫ Integration of 
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Figure 3. 4: The blurred dose gradient (c) is determined from the convolution of the static
dose (a) with derivative of PDF (b). The blurred dose including geometric uncertainties (d) 










Most of the organ motion studies give the mean and SD of motion in three orthogonal 
coordinate directions (Althof 1996, Balter 1995, Beard 1996, Crook 1995, Dawson 1998, 
Melian 1997, Roeske 1995, van Herk 1995, Zelefsky 1999). Doses at points along the 
anterior-posterior line through the isocenter were used to define the anterior-posterior 
doses for each patient, and the same method was used for the lateral and superior-inferior 
directions. The blurred dose gradient depends on the characteristics of the motion kernel 
as described by P and static dose gradient G0.  
PMDD in different directions was defined as deference between the mean dose of the 
dose points of blurred dose profile from isocenter to the edge of PTV and the mean dose 
of the whole PTV for the static dose distribution: 
Static Dose Gradient
PDF















Figure 3. 5: Steps used in calculating the blurred dose distribution including 
geometric uncertainties. 
 








PMDD ii                                            (3.12) 
where iMD  is the mean dose of dose points of the blurred dose profile from isocenter to 
the edge of PTV, the i represents one of the directions: left, right, anterior, posterior, 
superior or inferior. 0MD  is the mean dose of the whole PTV for static dose distribution 






















Figure 3. 6: MDi is the mean dose of dose points along the blurred dose profile from 
isocenter to the edge of PTV (dashed line). 
 
iPMDD  changes with the SD (σ) of the PDF. The SD can be obtained from the IGRT 
data. The PDF is patient specific. The population SD and patient specific SD were listed 












OMDS                                (3.13) 
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3.3  Results 
3.3.1   Target dose profile and convolution 
The dose profile across isocenter in AP, LR and SI directions for five-beam IMRT plans 
can obtained by exporting RTOG file data from the Pinnacle system. The resolution or 
dose voxel size is a user-defined parameter (typically 0.25 cm in all directions) which is 
specified prior to IMRT optimization. Increasing the resolution (i.e. reducing the dose 
voxel size) increases the time required for dose computation and optimization. The dose 
profile can also be obtained from the Pinnacle scripts directly. Different beam angle 
























Figure 3. 7: Static dose profiles along isocenter in A-P direction for five types of IMRT 
plans. 
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A Gaussian kernel is widely used and supported with a significant body of published data 
(Ten Haken 1991, Schild 1993, Balter 1995, Crook 1995, van Herk 1995, Lebesque 
1995, Roeske 1995, Beard 1996, Althof 1996, Melian 1997, Vigneault 1997, Dawson 
1998, Zelefsky 1999, Craig 2003a, 2003b). In this study, a Gaussian PDF with clinically 
realistic SDs for patient organ motion and repositioning uncertainty in three orthogonal 
coordinate directions were obtained in Chapter 2. Motion caused blurring dose 
distribution and thereby to a less conformal dose distribution in Figure 3.8 (five-field 
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Figure 3. 8: Dose profile along the SI direction and profiles with organ motion (Gaussian 
distribution with standard deviation sigma = 0.3, 0.5, 0.8, 1 and 1.2). 
Organ motion changes the dose distribution within the target volume. Because portions of 
the target volume can, in some cases, move outside of the high dose region that was 
planned to encompass them, a dose profile across this region of interest displays a 
broadening that is similar to an enlarged beam penumbra. Motion leads to a less steep 
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dose gradient and an enlarged dose profile penumbra at the edge of target. The amount of 
dose profile penumbra changing depends on the SD sigma and the dose gradient in the 
motion direction. The dose gradient is significantly deteriorated when internal organ 
motion is considered. When two dose profiles are compared, the difference between the 
dose with and without considering the organ motion is much greater for the sharper dose 
gradient as shown in Figure 3.8. The steepest gradient appears in the inferior direction 
(right) of the IMRT plan, while the dose gradient in superior direction (left) is not as 
sharp as that in inferior direction. 
3.3.2    Maximum Dose gradient 
The dose distribution falls steeply in the inferior direction for all the patients. Figure 3.9 
shows the dose gradients results for the same patient used in Figures 3.7 and 3.8 for one 
treatment plan.  The steepest gradient appears in the inferior direction of the IMRT 
planning. For five IMRT plans with different beam angles, the sharpest dose gradient 
appears in the inferior direction; as well, for five beam and seven beams, the inferior 
direction has the sharpest dose gradient as shown in Figure 3.10. In the case of a small 
prostate, sharp dose gradient appears in both in the superior and inferior directions. 
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Figure 3. 9: The static dose gradient (G0) from isocenter to anterior, posterior, superior, 
































Figure 3. 10: Absolute maximum dose gradient for different IMRT techniques. 
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3.3.3   Organ motion dose sensitivity (OMDS) 
The potential reduction in PTV dose coverage occurring at the edge of the PTV becomes 
a greater risk to the target with a sharper dose gradient. The motion sensitivity in anterior, 
posterior, left, right, superior and inferior directions with various dose gradients are 
evaluated by dose points along these directions within the PTV. PMDD was calculated 
from the dose difference between mean dose from isocenter to different directions within 
the PTV for the blurred dose profile and the mean dose within whole PTV for the static 
dose profile. The PMDD appears mostly in posterior direction for static dose distribution 
because of sparing the rectum intersection part of the IMRT planning as shown in Figure 
3.11. The rate change of PMDD is much higher in the inferior direction when internal 
organ motion is considered because of the higher dose gradient in inferior direction. The 
inferior direction has the sharpest dose gradient; therefore the motion has the most effect 
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Figure 3. 11: PMDD versus SD of PDF (Equation 3.12 in text). 
 
 
   94
In general, a sharper dose gradient leads to a bigger dose difference on the edge of PTV. 
The PMDD varies quasi-linearly with the maximum dose gradient between standard 
deviation equals 0.5 cm and 1 cm. The organ motion dose sensitivity is defined as the 
PMDD slope between values of σ = 0.5 cm and σ = 1 cm; OMDS increases with the 
maximum dose gradient in anterior, posterior, left and right directions as shown in Figure 
3.12. Dose gradients in superior and inferior directions are much higher than the left, 
right, anterior and posterior directions, due to common inferior and superior field borders 
of the field segments, the sharpest dose gradient will occur in the inferior direction or 
both the superior and inferior penumbrae. Thus, prostate motion in the SI direction 
produces the highest dose difference. From Figure 3.12, the OMDSs in superior and 
inferior directions are higher compared with other four directions. The PMDD with SD of 
organ motion are listed for three patients as representatives due to limited space, with 
small (17.3 cm3), medium (51.6 cm3) and large prostate (87.1 cm3) volume when SD 
equals 0.5 cm and 1 cm in Tables 3.2 and 3.3 respectively. Distribution into small, 
medium and large prostate volume was done to observe possible trends in terms of 
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Figure 3. 12: The organ motion dose sensitivity (Equation 3.13) versus maximum dose 
gradient. 
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Table 3. 2: PMDD with organ motion (standard deviation=0.5 cm). 
  Anterior Posterior Superior Inferior Left Right 
Combined 
effect 
Small prostate  
plan1 -0.3074 -0.2099 -1.3919 -1.2652 0.5320 -0.3867 -0.5049 
plan2 1.0520 1.4079 -0.3317 -4.1806 1.9472 0.4968 0.0653 
plan3 0.3960 -0.0227 -0.5723 -3.3583 0.3174 0.6685 -0.4286 
plan4 0.8164 0.6231 -0.1907 -4.6110 1.1735 0.7713 -0.2362 
plan5 -0.7123 0.6447 -1.1247 -2.1548 1.1746 0.3219 -0.3084 
Medium prostate  
plan1 -0.2309 -0.5280 0.0621 -0.9273 0.5473 1.0540 -0.0038 
plan2 0.6963 -1.0049 -1.5420 -0.4614 0.2392 1.0668 -0.1677 
plan3 0.0822 0.2264 -0.7634 -1.0548 0.2287 0.9703 -0.0518 
plan4 0.2637 -1.3195 -0.6622 -0.3986 0.8790 0.4557 -0.1303 
plan5 1.3458 -0.5359 -0.0618 -0.2317 1.3497 0.9489 0.4692 
Large prostate  
plan1 -0.8052 0.2641 0.2582 -0.1442 -0.3429 0.0610 -0.1182 
plan2 1.3287 -0.3737 -1.0387 -1.3441 0.3811 0.5032 -0.0906 
plan3 -0.7501 -0.8990 -0.8315 -2.0708 -0.2589 0.4913 -0.7198 
plan4 -0.5289 -1.5026 -1.1749 -1.6552 0.2414 0.0893 -0.7552 
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Table 3. 3: PMDD with organ motion (standard deviation=1 cm). 
  Anterior Posterior Superior Inferior Left Right 
Combined 
effect 
Small prostate  
plan1 -2.0706 -0.8252 -4.3194 -8.3127 -0.6288 -1.7378 -2.9824 
plan2 -0.4433 0.8291 -3.6323 -10.8452 0.5730 -0.5839 -2.3504 
plan3 -0.7728 -0.4655 -3.6226 -10.3785 -0.5959 -0.4859 -2.7202 
plan4 -0.1744 0.0891 -3.3109 -11.3708 -0.0410 -0.3323 -2.5234 
plan5 -1.9575 0.0387 -3.9888 -8.8874 -0.1531 -0.9647 -2.6521 
Medium prostate  
plan1 -2.2125 -1.6023 -2.4045 -5.1601 -1.1344 -0.3995 -2.1522 
plan2 -0.7891 -1.9366 -3.6474 -4.3970 -1.8611 -0.2200 -2.1419 
plan3 -1.1295 -0.8888 -2.7875 -4.9513 -1.3697 -0.2273 -1.8924 
plan4 -0.9688 -2.3458 -2.8256 -4.3181 -0.7776 -0.8393 -2.0125 
plan5 -0.3996 -1.4091 -2.3929 -4.0964 -0.0167 -0.7164 -1.5052 
Large prostate  
plan1 -2.5377 -0.6100 -2.6984 -4.1174 -1.6334 -1.3100 -2.1512 
plan2 -0.1187 -1.0833 -3.9053 -5.3519 -1.3138 -0.5328 -2.0510 
plan3 -1.8072 -1.7094 -3.7472 -6.0106 -1.8708 -0.7618 -2.6512 
plan4 -1.6618 -2.2881 -3.9881 -5.7985 -1.1006 -1.2016 -2.6731 
plan5 -0.8391 -0.6528 -3.5482 -4.8273 -1.0130 -0.8719 -1.9587 
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Figure 3. 13: Dose profiles and gradients for different IMRT planning techniques. 
Although sparing of both the rectum and bladder was considered during treatment 
planning; only the effects on rectum have been evaluated in detail in this study. Rectum 
sparing can be gained through reducing the margin of the PTV. However, CTV coverage 
is still important, and any PTV margin reduction should be facilitated by reduction of 
geometric uncertainties. The use of posterior margins of 1 cm to define the PTV in 
prostate treatment implies that portions of the anterior rectum will regularly receive the 
full prescription dose. Advances in IMRT have allowed greater separation between tumor 
control and normal tissue complications through improved dose distributions with steep 
dose gradients.  
Table 3. 4: Average NTCP with different margins and techniques. 
NTCP (%) 10mm 8mm 5mm 2mm 
5B_1 17.7 16 14.7 9.7 
7B_2 14.7 13.3 9.7 5.0 
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Different IMRT techniques are compared and the dose profile and gradient in posterior 
direction are shown in Figure 3.13. These technologies are exploited to maintain the 
escalated tumor dose constant but yielding different level of rectal complications. With 
the same DVH control points and different beams and beam angles, the rectum has less 
complication risk with the steepest dose gradient between the target volume and rectum 
in technique 7B_2 (40o, 80o, 110o, 250o, 280o, 310o, 355o).  
Technique 7B_2 has the sharpest dose gradient in posterior direction causing lower 
complications. The average NTCP for rectum for all the patients with different margins 
and two techniques are shown in Table 3.4. The margin was significantly associated with 
level of rectal complications. NTCP changes from 17.7% for a 10 mm margin to 9.7% for 
a 2 mm margin. However the results also revealed that the ability of IMRT techniques to 
reduce rectal complications depended on the techniques used. NTCP changes from 17.7% 
to 14.7% for a 10 mm margin, from 14.7% to 9.7% for a 5 mm margin for 7B_2 
technique compared to 5B_1 technique because of the steeper dose gradient in 7B_2 
technique. Margins are reduced for 7B_2 technique compared to 5B_1 technique to get 
the similar NTCP.  
The limitation of analyzing doses to the rectum lies in the fact that the rectum moves 
during the course of treatment, either by expanding or contracting, and by bulk motion in 
the anterior-posterior direction. The rectum can move 1 cm in the anterior-posterior 
direction with respect to the bony anatomy (Jackson 2001a). Geometric uncertainties can 
be assumed by rigid body translations of the patient anatomy. The rectum is assumed to 
be moved rigidly 1 cm in the anterior-posterior direction. The rectum has lower mean 
dose for 7B_2 (40o, 80o, 110o, 250o, 280o, 310o, 355o) compared to the other three 
techniques as shown in Figure 3.14. When the rectum moves in the high dose region, MD 
increases; while the rectum moves out the high dose region, MD decreases and decreases 
more sharply for the 7B_2 technique. 
 




































Figure 3. 15: Rectal NTCP versus AP shift. 
In Figure 3.15, with escalated higher prescribed dose and sharper dose gradient in 
posterior direction, the slope of NTCP reduction due to rectal motion from anterior to 
posterior direction, is sharper for 7B_2 technique compared to 5B_1 technique because of 
the sharper dose gradient in the posterior direction for 7B_2 technique. 
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3.3.5    The effect of geometric uncertainty on dose 
profile 
The patient was planned with a tight 2mm PTV margin, and then convolved with a PDF 
from the specific patient’s IGRT data. The patient-specific PDF could be selected and the 
patient plan was evaluated.  Table 3.5 showed the 20 patients’ prostate motion with mean 
and standard deviation in three directions. The first column showed the patient number 
and total fraction number for the patient. Prostate motion relative to bony anatomy in LR 
direction is less than those of AP and SI directions. The PDFs of Patient #6 and patient #7 
were selected to evaluate the percentage dose difference in AP direction, especially on 
the edge of target (cold spot). Figure 3.16 showed the percentage dose difference 
compared with prescription dose within PTV in AP direction. For patient #6, most of the 
motions are in the anterior direction, the dose difference is - 4.2 % in anterior direction; 
while for patient #7, most of the motions are in posterior direction, the dose difference is 
-3.5 % in posterior direction. Figure 3.17 showed the percentage dose difference 
compared with prescription dose within PTV in SI direction. For patient #1, most of the 
motions are in the inferior direction, the dose difference reached – 44.7 % in inferior 
direction; while for patient #3, most of the motions are in superior direction, the dose 
difference is – 5.1 % in superior direction. Figure 3.18 showed the result of patient #13, 
with the mean equals 2.6 mm in inferior direction, the dose difference is – 7.4 %. The 
inferior motion caused the most dose difference because of the sharpest dose gradient in 
the inferior direction. 
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Figure 3. 16: The dose difference for static 7F IMRT plan with a tight 2mm margin 
compared to the prescription dose within the PTV in AP direction. Static dose profile and 
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Figure 3. 17: : The dose difference for static 7F IMRT plan with a tight 2mm margin 
compared to the prescription dose within the PTV in SI direction. Static dose profile and 
profiles convolved  with the PDFs of patient #1 (red) and patient #3 (blue). 
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Figure 3. 18: The dose difference for static 7F IMRT plan with a tight 2mm margin 
compared to the prescription dose within the PTV in SI direction. Static dose profile and 
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Table 3. 5: Prostate organ motion for 20 patients in AP, LR and SI directions. 
Prostate AP LR SI 
unit: 
mm 
Mean SD Mean SD Mean SD 
P1(32) 0.22 2.57 1.00 0.70 7.18 2.01 
P2(27) 0.88 3.28 -0.30 0.75 1.04 2.41 
P3(29) -0.61 2.77 -1.66 0.85 -4.35 2.16 
P4(34) 1.74 2.46 -0.24 0.67 -1.47 1.88 
P5(34) 1.46 1.80 -0.21 0.88 -0.52 1.82 
P6(33) -3.15 2.15 -0.72 0.85 -2.36 2.24 
P7(37) 2.40 2.67 0.25 1.11 1.24 2.25 
P8(33) 0.66 2.46 -0.44 0.76 -1.37 2.29 
P9(33) -0.79 1.42 -0.52 0.41 -1.51 1.26 
P10(32) -0.97 2.44 0.72 1.07 -1.47 1.80 
P11(33) -0.56 1.92 -0.51 0.94 -2.49 1.83 
P12(34) -0.39 2.53 3.40 1.22 -1.71 2.19 
P13(31) 1.60 2.21 -0.61 0.94 2.58 1.68 
P14(35) -1.70 1.57 -0.03 0.63 1.17 1.82 
P15(35) -1.61 2.11 0.52 0.83 0.82 1.90 
P16(31) -0.64 2.33 -1.14 0.46 -1.73 1.42 
P17(34) 1.47 1.35 0.85 0.85 -0.30 1.20 
P18(34) -0.11 1.41 -0.09 0.60 -0.55 2.20 
P19(16) -0.07 1.20 0.20 1.42 0.34 1.62 
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3.3.6    Treatment plan vs. measurement 
 
 
Figure 3. 19: Beam arrangement for seven-field IMRT using Rando phantom. 
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Figure 3. 20: Treatment plan vs. measurement: seven beam IMRT for prostate bed 
(central plane). 
The validity of a treatment planning system-based dose gradient analysis can be tested by 
comparing planned and measured results. The dose distribution resulting from a seven-
field IMRT plan was compared to both film and ion chamber array measurements for the 
7 field geometry depicted in Figure 3.19. The isodose line comparison between the 
treatment plan and film measurement is shown in Figure 3.20. The thin lines are the 
Pinnacle treatment planning system result; the thick lines are the film measurement 
result. A similar level of agreement was seen in the coronal ion chamber array 
measurements.  The seven beam composite isodose comparison for prostate bed 
treatments (double concave “dumbell shaped” target) shows that the treatment planning 
system is accurate and consistent with measurements, especially in the high dose regions 
from isocenter to the anterior or the posterior direction. The result shown above is for a 
single plan vs. measurement comparison.  To date, many plans and measurements have 
been compared with similar levels of agreement. The excellent agreement between the 
Thin Lines    – Pinnacle TPS 
Thick Lines – Film Measurement
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treatment planning system and measured data validates the treatment plan-based dose 
gradient analysis method. 
3.4   Discussions 
The outcome of clinical trials is dependent on dose accuracy; 5% accuracy is desirable 
and assuming that uncertainties in each procedure are random in nature, then the required 
accuracy for each step is 2.5% (ICRU50 1993, ICRU62 1999, Van Dyk 1999). In the 
Tables 3.2 and 3.3, the PMDD with SD of organ motion are listed for all the five plans. 
The PMDD is within 2.5% in the anterior, posterior, superior, left and right directions, 
just two plans for small prostate are above 2.5% in the inferior directions when SD equals 
to 0.5 cm. The PMDD reaches 11% for a small prostate moving along the inferior 
direction when SD equals to 1 cm.  
The standard deviation for prostate and seminal vesicle motion from the studies ranged 
from 0.7 to 3.2 mm in the LR dimension, 1.5 to 7.3 mm in the AP dimension, and 1.7 to 
6.5 mm in the SI dimension (Alasti 2001, althof 1996, Balter1995, crook 1995, Hoekstra 
1996, Jiang 2007c, little 2003, Melian 1997, Rudat 1996, van Herk 1995, Vigneault 
1997). As reported by Melian et al (1997), one SD translations of the prostate was 4.0 
mm in AP compared to 3.1 mm in SI. Similar observations were made by Rudat et al. 
(1996) with 6.1 mm in AP, 3.6 mm in LR, 6.5 mm in SI for the combined effect of 
patient repositioning and prostate motion for prostate patients. Although no major bias 
for anterior movements was found over posterior movements, a bias was discovered for 
inferior motion over superior motion (Alasti 2001). This result is consistent with findings 
by Crook et al (1995), who reported 43% of patients as having inferior displacements 
greater than 5 mm and 11% greater than 10 mm. This predominant motion in the inferior 
direction was attributed to a reduction in the distension of the rectum during a course of 
radiation therapy. In our study, the inferior direction has the sharpest dose gradient. When 
the prostate moves inferiorly, it could move out of the high dose region and cause a much 
higher dose deficiency. As noted earlier, there is the steepest dose falloff outside of the 
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PTV in inferior direction. The inferior motion is expected to cause a higher PMDD 
within the PTV. If SD is less than 5 mm, the PMDD is within 2.5%. But if SD is higher 
than 5 mm in S-I direction, the PMDD is over 2.5% in inferior direction. Therefore the 
patient QA checking of treatment plan for prostate patients in inferior directions is 
essential. 
For prostate motion, AP movement is larger than the LR; the preference for AP motion 
was first explained through the correlation of prostate motion with bladder and rectum 
fillings by Ten Haken et al (1991). The movement is correlated to the bladder and rectal 
filling (Balter 1995, Beard 1996, Roeske 1995). In the AP direction, the average motion 
varied from 0.2 mm to 6.4 mm, with SDs ranging from 3.9 mm to 6.7 mm, no major 
preference for anterior movements was found over posterior movements (Alasti 2001). 
AP motion would cause complication to the rectum. In our study, the ways to reduce the 
rectal complication can be realized by either smaller margin or steeper dose gradient. 
Following the ICRU-62 (1999) recommendations, uncertainties during radiation therapy 
treatments are generally included in the treatment planning by adding a margin to the 
CTV to yield the PTV. Large margins result in a high level of confidence that the CTV is 
adequately covered during treatment. However, PTV overlaps with OAR (ICRU50 1993, 
ICRU62 1999), which is the case in the prostate patient.  The overlap part of rectum and 
PTV will receive the full prescription dose. Smaller margins and more conformal dose 
distributions are helpful means to reduce the dose to the rectum, but may compromise the 
dose coverage of the PTV. However, steep dose gradient between PTV and rectum works 
well to maintain TCP and reduce NTCP. 
In IMRT, the dose distributions are increasingly conformal with an introduction of dose 
gradients within the PTV in an effort to avoid higher incidences of rectal complications 
with higher prescribed dose. The shaper dose gradient in posterior direction can be 
obtained by either different planning techniques or adjusting DVH controls points in 
IMRT optimization. Dose gradient has relationship with the number of the beams and the 
selection of beam angles. The rectum has lower complication with the steepest dose 
gradients between the target volume and critical structures in technique 7B_2, which 
geometrically avoids the rectum, but still provides excellent coverage of PTV.  
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The dose gradient is a product of the optimizer, dose objective function and constraints, 
while specification of controls points is insufficient to set the dose gradient because the 
dose gradient D∇  also has relation with the beams and beam angles. The results show 
that the rectum has lower NTCP for 7B_2 (40o, 80o, 110o, 250o, 280o, 310o, 355o) 
technique with same control points. The dose gradient is a sensitive function of DVH 
control points of commercial optimization algorithms; the maximum dose gradient should 
be determined by adjusting DVHs control points for individual patients or by putting an 
additional shell around PTV to constrain the shell dose with DVH control points. This 
will be discussed further in next chapter. 
3.5   Chapter Summary 
Dose gradient and PDF were used to evaluate the effect of internal organ motion for 
IMRT treatment planning of prostate cancer. The PMDD depended on the dose gradient 
and PDF. OMDS was defined by the rate of change in PMDD with SD of Gaussian PDF 
and was found to increase with the maximum dose gradient in anterior, posterior, left and 
right directions. Due to common inferior and superior field borders of the field segments, 
the sharpest dose gradient occurred in the inferior or both superior and inferior directions. 
Thus, prostate motion in the SI direction produced the highest dose difference. The 
PMDD is within 2.5% when SD is less than 5 mm, but the PMDD is over 2.5% in 
inferior direction when SD is higher than 5 mm in inferior direction. Verification of 
organ motion in the inferior directions is essential. Lower rectal NTCP can be achieved 
by either smaller margin or steeper dose gradient between the PTV and rectum. With the 
same DVH control points, the rectum had a lower complication in the 7B_2 technique 
because of the steeper dose gradient between the target volume and rectum. The 
relationship between dose gradient and rectal complication probability can be used to 
evaluate the IMRT treatment planning. Dose gradient analysis is a powerful tool to 
evaluate IMRT treatment plan and can be used for QA checking of treatment plan for 
prostate patients. 
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Chapter 4 
The Effect of Dose Gradient on 
Rectal NTCP 
Rectal complication in intensity-modulated radiation therapy (IMRT) prostate treatment 
planning was evaluated using spatial dose distribution and dose gradient around overlap 
region of prostate and rectum. Dose distributions were generated from a Pinnacle 
planning system using five-field (5F) and seven-field (7F) co-planar IMRT techniques 
with an escalated dose of 82Gy. Local maximum dose gradient (LMDG) were obtained in 
the transverse and sagittal planes and analyzed to find the relationships between LMDG 
and organ motion dose sensitivity (OMDS), tumor control probability (TCP) and normal 
tissue complication probability (NTCP). In the transverse plane, LMDGs exhibited a 
large variation for a 5F plan and were lowest in posterior direction. However, the 
variation decreased significantly with increasing beam number. In the sagittal plane, the 
highest LMDG occurred in the inferior direction or both the superior and inferior 
directions. The OMDS were much higher in SI direction than LR and AP directions, due 
to common inferior and superior field borders of the field segments. Thus, prostate 
motion in the SI direction produced the highest impact on the target dose. Without 
compromising target dose distribution, LMDG in posterior direction was increased 
further by adjusting rectal DVH control points. Relative to 5F plans, 7F plans 
demonstrated a higher LMDG in the posterior direction. The higher LMDG in the 
posterior direction can be obtained either by modifying the planning technique or 
adjusting rectal DVH control points. The NTCP was reduced with a higher LMDG 
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between PTV and rectum. LMDG determined from commercial IMRT solutions can be 
increased further in the posterior direction by manually adjusting DVH control points. By 
achieving the higher dose gradient in posterior direction, rectal dose and NTCP were 
improved relative to current RTOG IMRT prostate protocols.  
4.1  Introduction 
IMRT has developed rapidly in recent years. Despite improving planning technique, 
delivery skills, the use of sophisticated localization procedures and 4DCT, the irradiated 
high-dose volume inevitably includes some portions of the bladder and the rectum. 
Margins are needed around the prostate to account for the uncertainties, such as setup 
error and prostate motion (Vigneault 1997, Lattanzi 1999, Kitamura 2002, Morr 2002, 
Nederveen 2002). Dose escalation with IMRT for prostate cancer has been limited by the 
tolerance of the surrounding normal structures such as the rectum and bladder. The 
increase in target prescription dose carries a potential risk of inducing chronic toxicity for 
the normal tissue. The IMRT prostate treatment plan uses specific the dose volume 
histogram (DVH) control points for the rectum and bladder to determine the treatment 
dose level (Yan  2000, Martinez 2001). The target dose is prescribed to meet the 
predetermined rectum and bladder constraints based on different dose-volume limitations 
of rectum and bladder. A lack of knowledge about safe dose–volume constraints may 
lead to inappropriate dose delivery with IMRT: an excessively cautious approach to 
rectum sparing may increase the risk of missing or underdosing the target, whereas the 
irradiation of large fractions of rectum may result in patients’ experiencing 
moderate/severe bleeding. 
A precise understanding of the tolerance of these two organs is essential because it 
ultimately limits the dose to the target. Despite the large number of prostate cancer 
patients treated with 3D-CRT, the reported knowledge of bladder and rectum tolerance is 
still quite unclear and not amenable to being used prospectively (Jackson 2001b, O'Brien 
2001). This is due to multiple problems including the lack of standardization of tolerance 
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scoring or assessment, the lack of detailed and systematic data on individualized 
dosimetry, and inconsistency in rectal and bladder volume definitions. 
Previous studies have shown a close relationship between chronic rectal toxicity and 
rectal dose volume histogram findings. Several authors have found the relation between 
chronic rectal toxicity and the volumes of the rectum or rectal wall irradiated to doses 
≥50 Gy (Benk 1993, Boersma 1998, Skwarchuk 2000, Jackson 2001a 2001b, Wachter 
2001, Fiorino 2002b, Kupelian 2002a). Some reports have clearly indicated a significant 
dose–volume dependence of late rectal injury (the so-called volume effect) (Cheng 1999, 
Jackson 2001a, Wachter 2001, Fiorino 2002b, Huang 2002b, Chism 2003). The RTOG 
toxicity scale is often used to report acute GI and GU toxicity since its publication in 
1995 (Zelefsky 1995 2002a, Pollack 1996, Kupelian 2002a, O'Brien 2002, Ruy 2002). 
IMRT treatment enables us to treat patients without an increase in acute GI toxicity 
because it provides more degrees of freedom for shaping dose distribution to produce 
highly conformal dose coverage of PTV and significantly reducing the dose to the 
rectum. Rectal dose has been considered the most significant factor associated with the 
risk of Grade 2-4 complications (Zelefsky 1998, Michalsk 2000; Skwarchuk 2000; Storey 
2000; Wachter 2001; Pollack 2002). The higher rectal dose we tolerated could be 
responsible for the difference in acute toxicity.  
IMRT is efficacious in permitting safe dose escalation by reducing radiation exposure to 
dose-limiting normal tissues (Zelefsky 2002a, 2002b). However, in order to keep rectal 
toxicity at acceptably low levels, knowledge of the dose–volume relationship within a 
specific patient population must be acquired for a certain treatment setup, so that 
appropriate treatment constraints may be confidently applied (Lyman 1987, Kutcher 
1996). Some studies have been performed to correlate DVH patterns and late rectal 
toxicity (Boersma 1998, Storey 2000, Fenwick 2001c, Jackson 2001b, Fiorino 2002b). 
There is a dose–volume relationship for rectal bleeding in the region between 60 and 75 
Gy. Boersma et al (1998) reported on DVH analysis of a group of 130 patients treated in 
a 3D-CRT dose escalation protocol (70–78 Gy isocentre dose). None of the DVH 
parameters was significantly correlated with the actuarial incidence of GI complications 
grade 2 which was as high as 14% at 2 years. However, for severe rectal bleeding, three 
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dose–volume levels were found, which significantly discriminated between high risk and 
low risk groups: 65 Gy to 40% of the rectal wall, 70 Gy to 30% and 75 Gy to 5% of the 
rectal wall. When more than 25% of the rectum received 70 Gy, Storey et al (2000) 
showed evidence for a significant increase in late rectal complications. Furthermore, all 
grade 3 complications occurred when 30% of the rectum received 70 Gy. An update of 
the toxicity outcome of this study by Huang et al (2002) with a median follow-up of 5 
years and more extensive DVH analysis, showed a strong relationship between dose and 
volume. To reduce the risk of late toxicity they identified the following cut-points: <40% 
of the defined rectal volume should receive 60 Gy, <25% should receive 70 Gy, <15% 
should receive 75.6 Gy, and <5% should receive 78 Gy. DVH data from these studies 
clearly indicate that the percent volume of rectum exposed to doses above 60–70 Gy 
plays a crucial role in determining radiation-induced rectal morbidity.  
The investigations mentioned above have reported relationships between rectal dose–
volume data and clinically observed rectal complications. However, few studies specify 
the spatial dose distribution, such as dose gradient as an indicator of how conformal the 
dose coverage actually is and its effect to the target and normal tissue (Jiang et al 2007a, 
2007b). Although DVHs are important planning parameter and are linked to TCP and 
NTCP, they do not contain spatial dose distribution information and are therefore not as 
effective as the dose gradient.  
The dose profile and dose gradient analysis are carried out to present the dose distribution 
of a chosen voxel sequence of the 1D interest in this study. The aim of this study is to 
find dose–volume constraints for IMRT inverse-planning algorithm with an escalated 
dose of 82 Gy by analyzing the dose profile and dose gradient. The rectum receives 
higher dose with escalated prescription dose, however the rectal DVH control points were 
pulled down as much as possible without compromising target dose coverage judged by 
dose profile and gradient. Although sparing of both the rectum and bladder was 
considered during treatment planning; only the effects on rectum have been evaluated in 
detail in this study. Dose gradient analysis is completely general and is independent of 
optimization algorithm. The analysis of the dose gradient is a useful tool for judging of 
IMRT treatment plan. 
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4.2   Methods and Materials 
4.2.1    Patients 
IMRT Treatment plans are created for fifteen prostate patients, covering a range of 
prostate target volumes from 17.3 cm3 to 87.1 cm3, and different overlap of planning 
target volume (PTV) with organ at risk (OAR). The prostate, seminal vesicles, bladder, 
rectum, and femoral heads of the prostate patients were contoured by the therapist using 
CT data. Two PTVs for each patient are generated: PTV1 includes the prostate and 
seminal vesicles plus a 10 mm margin; PTV2 includes the prostate only plus 10 mm 
margin. Table 4.1 shows the volume range and standard deviation of PTVs and OARs 
determined from Pinnacle3.  




Rectum Bladder PTV2 PTV1 Femur 
17.3 to 87.1 5.8 to 24.9 44.9 to 217.6 44.4 to 520.1 78.1 to 254.9 141.1 to 314.1 134.1 to 223.1 
45.2±18.3 13.3±5.8 98.25±44.9 232.3±44.4 153.7±43.3 218.4±46.8 172.1±25.1 
  
4.2.2   IMRT treatment planning and objective 
functions 
All cases were planned for supine patient treatment using a 6 MV photon beam from 
Varian 21EX linear accelerator (Varian Medical Systems, Palo Alto, CA). All were 
devised for coplanar treatment with the long axis of the patient couch parallel to the axis 
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of the treatment machine gantry rotation. The prostate IMRT inverse treatment planning 
was optimized with a coplanar, isocentric five-field (5F: 0o, 72o, 144o, 216o, 288o) and 
seven-field (7F: 40o, 80o, 110o, 250o, 280o, 310o, 355o) techniques. 
Table 4. 2: DVH control points (Gy) from RTOG P-0126. 
PTV2 PTV1 Rectum Bladder Femur 
D2% ≤ 86 D95% = 56 D15% = 75 D15% = 80 D2% ≤ 40 
D95% = 82 Dmin = 54 D25% = 70 D25% = 75 … 
Dmin = 80 … D35% = 65 D35% = 70 … 
… … D50% = 60 D50% = 65 … 
 
An escalated prescription dose of 82 Gy (2 Gy per fraction) was prescribed for all IMRT 
plans. The DVH control points for the PTV and OARs were adapted from RTOG 0126 
protocol (2004) as shown in Table 4.2. DV% is the dose (Gy) allowed for percentage 
volume (%). The minimum and maximum dose to the target and maximum dose to the 
OARs are parameters in the optimization cost function. The relative weights were 
adjusted by changing the DVH control points of the PTV and OARs for the IMRT plans. 
All patients were planned using the same objectives and constraints for PTVs and bladder 
but different for rectum in plan1 and plan2 as shown in Table 4.3, rectal DVH control 
points were lowered down as much as possible in plan2 without compromising PTV 
coverage. For each PTV, 3D uniform margins of 10 mm were used in plan1 and plan2; 
non-uniform margins of 5mm in posterior direction and 10mm margins in other 
directions were used in plan3. While rectal DVH control points in plan 2 and plan3 are 
same but plan2 with uniform margin and plan3 with non-uniform margin (5 mm in 
posterior direction and 10 mm in other directions). A 3D dose distribution was calculated 
using the Pinnacle inverse treatment planning system.  
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Table 4. 3: DVH control points (Gy) of rectum and bladder for different plans. 
               




D15% D25% D35% D50% 
Rectum 75 70 65 60 
Plan1 PTV1,2=CTV+1cm  
Bladder 78 70 65 45 
Plan2 PTV1,2=CTV+1cm Rectum 70 60 50 45 
Plan3 PTV1,2=CTV+0.5~1cm
}
Bladder 78 70 65 45 
 
4.2.3   Dose profile and LMDG 
Doses at points along the specific line from the isocenter to different direction were used 
to define the dose profile in that direction for each patient. The dose gradient gives the 
slope of the dose fall in that direction and can be derived from dose profile. The dose 
gradient used in this study is the absolute value of dose gradient. The dose profiles are 
determined from the isocenter to a specific direction in the transversal plane and sagittal 
plane in vicinity of posterior directions. The magnitude of the dose gradient will tell how 
fast the dose falls in the specific direction. The LMDG is the steepest slope of the dose 
profile outside of PTV.  
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4.3   Results 
4.3.1    LMDG in transverse and sagittal planes  
Figure 4.1 shows the LMDG in the transverse and sagittal planes for two randomly 
selected patients. In the transverse plane for a 5F plan, there is a large variance in the 
LMDG with the lowest value in the posterior direction. By increasing the number of 
IMRT beams to seven, however, there is a significantly lower variance along with a 
higher LMDG in the posterior direction and lower LMDG in lateral direction in Figure 
4.1 (a). In the sagittal plane, the largest LMDG appears in the inferior direction for both 
5F and 7F plans, and there is higher LMDG in superior direction as shown in Figure 4.1 
(b). The organ motion had the most effect on the target dose in the inferior direction or 
both superior and inferior penumbrae (Jiang et al 2007a). The LMDG in sagittal plane in 
Figure 4.1 (b) shows the same result that lowest LMDG appeared in posterior direction 
for 5F plan. 
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Figure 4. 1: LMDG for two randomly selected patients in (a) transverse plane and (b) 
sagittal plane. 
 
4.3.2   Dose profiles and LMDG in sagittal plane 
The profiles from isocenter in directions where the PTV and rectum overlap in Figure 4.2 
were used to analyze the effect of LMDG on rectum. The profiles show that 7F plan have 
much lower dose in the dose region from 40Gy-70Gy than that of 5F plan in Figure 4.2. 
The dose profile for 5F1 is the highest one for all the profiles in vicinity of the posterior 
direction, and there is plateau around 50 to 60Gy. The beam number and beam direction 
affect the dose profiles in the area where the PTV and rectum overlaps. The profiles in 
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control points in plan2 pull down the profile in vicinity of the posterior direction. With 
non-uniform margin in plan3, dose profile drops down compare with uniform margin in 



























Figure 4. 2: Dose Profiles in sagittal plane from isocenter to posterior direction (α=0o).  
The LMDG is obtained every five degrees between 0° to 15° in vicinity of the posterior 
directions in the sagittal plane for different IMRT techniques. The LMDG distance from 
isocenter is the distance from the isocenter to the position where the dose gradient 
reaches maximum, as shown in Figure 4.3. LMDG in vicinity of the posterior direction, 
LMDG distance from isocenter and rectal NTCP for one patient are shown in Figure 4.4 
(a), (b) and (c), respectively. LMDG increases from plan1 to plan2 because of lower 
rectal DVH control points, and LMDG increases from plan2 to plan3 because of the non-
uniform margin for plan3 in Figure 4.4 (a) for both 5F and 7F plans. The distance of 
LMDG position from isocenter is shorter from plan3 to plan2 and from plan2 to plan1 in 
Figure 4.4 (b), the corresponding dose outside of edge of PTV decreases quickly with 
higher LMDG and shorter LMDG distance from isocenter which cause lower NTCP in 
Sagittal plane: 
The profile from 
isocenter to the 
posterior direction 
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Figure 4.4(c). The LMDG in vicinity of the posterior direction should be higher enough 
to ensure the dose fall off quickly to avoid the rectal complication. 
            














            




















LMDG distance from isocenter 
 
Figure 4. 3: LMDG distance from isocenter.  
 
 































































Figure 4. 4: (a) LMDG in vicinity of posterior direction, (b) LMDG distance from 
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4.3.3   Rectal dose at different percentage volume 
For prostate cancer, the treatment dose is prescribed based on different dose-volume 
limitations of bladder and rectum defined as the pretreatment reference. The dose is 
prescribed so as to meet the predetermined PTV, rectum and bladder DVH constraints 
and objective functions. The rectum DVH control points were established from the 
RTOG P-0126 protocol (2004) for treatment planning. IMRT can permit safe dose 
escalation by reducing radiation exposure to dose-limiting normal tissues. The need for 
finding reliable dose-constraints is vital in order to keep rectal toxicity at acceptably low 
levels without compromising PTV. The percentage of rectal volume exposed to 45, 50, 
60, and 70 Gy were limited to 50, 35, 25, and 15%, respectively in plan2. Table 4.4 
shows DV% for 5F and 7F plans with different DVH control points for randomly selected 
three patients include different rectum and bladder volume combination due to limited 
space. The average DV% decreases from plan1 to plan2 for both 5F and 7F plan. 5F1 has 
obvious higher dose covering large portion of rectum. The DVH control points in 5F2 
lowered the rectal DVH down to reduce the rectal dose, similar to 7F plan; however, the 
rectal dose DV% (Gy) at different rectal percentage volume (V%) value in 7F1 is lower 
than 5F1 in Table 4.4.  
4.3.4   Rectal percentage volume at different dose 
level  
Table 4.5 shows the rectal percentage volumes at dose level 50Gy, 60Gy and 70Gy; mean 
dose, NTCP and average LMDG for 5F and 7F plans with different DVH control points. 
5F1 has highest rectal percentage volume for all the patients.  
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Table 4. 4: Rectal dose (Gy) at different rectal percentage volume (DV%) for three 
randomly selected patients. 
               
   Patients Plans D15% D25% D35% D50% 
   
   
 
Prostate:  5F1 78.4 72.3  66.2 59.1 
    51.58cm3 5F2 75.8 66.8 57.1 47.2 
    Rectum: 5F3 74.9 64.3 55.2 46.8 
    82.87cm3 7F1 78.2 68.4 58.0 44.9 
    Bladder: 7F2 76.0 64.9 55.4 43.5 





Prostate:  5F1 78.2 71.0 65.7 59.4 
    56.03cm3 5F2 75.0 64.4 56.8 49.1 
    Rectum: 5F3 72.1 62.2 55.6 48.2 
    217.57cm3 7F1 73.8 61.4 54.6 42.4 
    Bladder: 7F2 72.2 60.0 53.8 42.0 





Prostate:  5F1 78.8 73.4 68.3 61.9 
    87.08cm3 5F2 76.5 70.0 62.4 51.8 
    Rectum: 5F3 76.2 67.2 58.2 49.7 
    76.65cm3 7F1 79.2 71.7 64.1 56.2 
    Bladder: 7F2 77.8 68.7 58.2 49.1 
    290.68cm3 7F3 74.7 63.8 55.3 48.7 
 
 









Table 4. 5: Rectal percentage volume (%) at different dose level (VDGy) for three 
randomly selected patients. 
               































51.58cm3 5F2 43.3 31.3 21.0 50.2 12.3 25.8 
Rectum: 5F3 41.5 29.1 18.6 48.6 12.9 34.1 
82.87cm3 7F1 42.6 32.5 22.6 47.2 14.0 35.8 
Bladder: 7F2 40.5 29.7 19.7 46.1 12.4 34.0 

























56.03cm3 5F2 47.4 29.3 18.8 48.4 12.0 24.1 
Rectum: 5F3 45.4 26.9 16.2 46.9 9.9 24.2 
217.57cm3 7F1 40.3 25.7 17.0 43.6 11.1 48.9 
Bladder: 7F2 39.6 24.2 15.7 43.1 10.6 47.7 

























87.08cm3 5F2 53.2 37.7 24.5 54.5 14.0 17.6 
Rectum: 5F3 48.7 32.4 21.6 52.5 12.9 26.2 
76.65cm3 7F1 63.7 41.2 26.4 55.8 17.0 40.8 
Bladder: 7F2 46.9 32.3 22.8 52.2 15.5 34.9 
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Figure 4. 5: Average rectal dose (Gy) at different percentage volume for different 
techniques (a) 5F, (b) 7F for all patients. 
The sharper dose profiles in posterior direction, the lower dose at rectal percentage 
volume as shown in Figure 4.5. With the 7F plan, there is a natural reduction in the rectal 
dose at specific percentage volumes; also it is possible to lower the rectal DVH control 
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points further to obtain a better dose gradient without sacrificing or impacting on other 
constraints for the IMRT plans. D15%, D25%, D35% and D50% decrease 4%, 8%, 13% and 
18% respectively from 5F1 to 5F2, while for 7F plan, the rectal dose decreasing from 7F1 
to 7F2 is 3%, 5%, 7% and 8%, respectively. The 5F1 has highest dose at different rectal 
percentage volume; D15%  in plan2 is lower than 75Gy for 5F plan and 7F plan. For non-







































Figure 4. 6: Average rectal percentage volume, mean dose (MD), NTCP and LMDG for 
(a) 5F and (b) 7F plans for all patients. 
Relative to a 5F plan, the 5F plan demonstrates a higher LMDG in the posterior direction 
causing lower rectal complications. In Figure 4.6, the average rectal percentage volume 
V50Gy, V60Gy and V70Gy decreased 37%, 38% and 26% respectively from 5F1 to 5F2, while 
for 7F plan, the rectal percentage volume decreasing from 7F1 to 7F2 is 16%, 19% and 
13% respectively. The average mean dose and NTCP decreasing are 13% and 29% from 
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5F1 to 5F2, and 5% and 13% from 7F1 to 7F2. For non-uniform margin, the NTCP 
decrease 10% for 5F plan and 17% for 7F plan. To achieve the high LMDG, V70Gy, V60Gy 
and V50Gy of the rectal DVH are below 21%, 32% and 48%, respectively. These values 
are lower than RTOG guideline (25%, 35% and 55%, respectively) and do not 
compromise the dose distribution elsewhere. 
4.4   Discussions 
4.4.1    Dose profile and LMDG  
The increase in prescription dose for the target carries a potential risk of higher rates of 
rectal chronic toxicity. The importance of reliable dose–volume constraints in treatment 
planning is becoming more apparent with IMRT. Few studies have previously focused on 
dose profile and dose gradient as end points of commercial optimization algorithms 
(Jiang et al 2007a). The DVH data clearly indicate that the percent volumes of rectum 
were lowered with lower rectal DVH control points either for the 5F plan or 7F plan; 
With the same DVH control points and different beams and beam angles, the rectum has 
lower complication in 7F plan, which has the sharper dose profile and higher LMDG in 
the posterior direction between the target volume and critical structures as shown in 
Figure 4.4. The study shows that 7F plan has sharper dose profile in posterior direction 
causing lower rectum complications. The results revealed that IMRT technique has the 
ability to redistribute the dose to achieve high LMDG in a particular region with some 
loss of dose gradient elsewhere.  
The sharper dose profile and higher LMDG in the posterior direction can be obtained by 
either different planning technique (5F to 7F) or adjusting DVH controls points (plan1 
comparing to plan2) in IMRT optimization. The rectum has lower complication with the 
steeper dose profile and higher LMDG between the target volume and rectum, which 
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geometrically avoids the rectum with adjusted DVH control points, but still provides 
excellent coverage of PTV. 
In IMRT, the dose distributions are increasingly conformal with an introduction of high 
LMDG on the edge of the PTV in an effort to avoid higher incidences of rectal 
complications with higher prescribed dose. LMDG is a function of DVH control points, 
also a product of optimizer, dose objective function and optimization constraints. The 
sharper dose profile and higher LMDG in posterior direction can be obtained by either 
different planning techniques or adjusting DVH controls points in IMRT optimization. 
The LMDG around posterior direction should be higher enough to ensure the dose fall 
quickly to avoid the rectal complication. 
4.4.2  DVH comparison for patients with and without 
bleeding 
Several investigations have reported relationships between rectal dose–volume data and 
clinically observed rectal complications. Storey (2000) et al reported a correlation 
between rectal toxicity and V70Gy in 91 patients treated with 3D-CRT at 78 Gy: the late 
Grade 2–3 rectal bleeding was 12% and 28%, respectively, for patients with VD70 lower 
or higher than 25%; Jackson (2001b) et al suggested that the irradiation of large fractions 
of the rectum at intermediate dose around the portion of rectum irradiated at high dose 
may result in a loss of repair capacity of the mucosa cells, which may lead to bleeding. 
Fiorino (2002) et al found several DVH constraints to be significant in a population of 
229 patients treated at 70–76 Gy (ICRU dose) in three of the four institutions. In the 
article by Huang (2002) et al, the fraction of rectal volume receiving more than 60, 70, 
75.6, and 78 Gy was found to be predictive of late moderate/severe rectal toxicity. 
Optimal cutoff values were suggested to be 40.6%, 26.2%, 15.8%, and 5.1% for V60Gy, 
V70Gy, V75.6Gy, and V78, respectively. Based on Fiorino (2003) et al.’s results, optimal 
dose–volume constraints for 3D-CRT and IMRT planning optimization: V50Gy below 60–
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65%, V60Gy below 45–50%, and V70Gy below 25–30% should keep the rate of late 
bleeding (Grade 2–3) below 5–10% for an ICRU dose between 70 and 78 Gy. Our results 
in Figure 4.5 show: V70Gy below 25%, V60Gy below 35% and V50Gy below 55% for plans 
5F2, 5F3, 7F1, 7F2 and 7F3, respectively.  
The rectal dose value of D15%, D25%, D35% and D50% should be below 75Gy, 70Gy, 65Gy 
and 60Gy, respectively for RTOG 0126 (2004) treatment planning guideline. Figure 4.4 
shows the rectum D15%, D25%, D35% and D50% are below 75Gy, 70Gy, 65Gy and 60Gy, 
respectively, for 5F2, 5F3, 7F2 and 7F3 with prescription dose 82 Gy. The constraints in 
treatment plan2 fulfill the guideline with escalation dose 82Gy.  
4.4.3   Mean dose and NTCP 
If the value of mean dose of the rectum was used as a cutoff value for predicting late 
rectal bleeding, Tucker (2004) et al predicted rectal bleeding for patients with rectal mean 
dose (MD) >56.3 Gy and no bleeding for patients with MD < 56.3 Gy. The average mean 
dose in our research shows the mean dose is lower than 51 Gy for all the plans except 
5F1, which is 58.5 Gy. The mean dose decreases 4% and 6% for 5F plan and 7F plan 
respectively with non-uniform smaller margin at the prostate–rectum interface in plan3.  
PTV overlaps with OAR (ICRU50 1993, ICRU62 1999), which is the case in the prostate 
patient. The ways to reduce the rectal complication can be realized by either non-uniform 
margin or steeper dose profile and higher LMDG between the PTV and rectum. The 
overlap part of rectum and PTV will receive the full prescription dose, the more 
conformal dose distributions are helpful reduce the dose to the rectum, but may 
compromise the dose coverage of the PTV. However, steep dose profile and higher 
LMDG between PTV and rectum works well to maintain TCP and reduce NTCP. 
Rectal volume changing during the treatment course may significantly affect the actual 
dose distributions, thus influencing the reliability of DVHs derived from the initial CT 
scan (Lebesque 1995; Roeske 1995; Tinger 1998; Wu 2001). The initial DVH from the 
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simulation CT must be regarded as a rough approximation. Nevertheless, the results of 
the current analysis do show a correlation between the dose profile of rectum and late 
rectal morbidity, even if the effects of treatment uncertainties are not accounted for. The 
research for rectal motion is further discussed in another paper. 
4.5   Chapter Summary 
Rectal complication probability in IMRT prostate treatment planning was evaluated using 
spatial dose distribution and LMDG to find the reliable dose–volume constraints for 
IMRT inverse-planning with an escalated dose of 82Gy. The LMDG is dependent upon 
the IMRT treatment technique, and DVH control points, also it is a product of the 
optimization routine. The sharper dose profile and higher LMDG in posterior direction 
can be obtained by either different planning technique or adjusting rectal DVH controls 
points in prostate IMRT optimization. 7F plans have higher LMDG than 5F plans. The 
profiles from isocenter to the directions where the PTV and rectum overlaps show the 7F 
plans have much lower dose in the dose region from 40Gy-70Gy than that of 5F plans. 
Steeper dose profiles and higher LMDGs between the PTV and rectum work well to 
maintain TCP and reduce NTCP. The LMDG in the posterior direction should be high 
enough to ensure the dose fall off quickly to avoid high rectal complication probability. 
The results show that 7F plans have sharper dose profile around posterior direction and 
resulting in lower rectum complication probability. V70Gy V60Gy and V50Gy are below 25%, 
35% and 55% respectively for 5F2, 5F3, 7F1, 7F2 and 7F3 for all the patients. The 
adjusted DVH control points fulfill the RTOG guideline with dose escalation to 82Gy. 
LMDG analysis is a powerful tool for judging the quality of IMRT treatment plans and 
can be used for QA of treatment plans for prostate patients. 
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Chapter 5 
 
The Cumulative Rectal Dose 
Incorporating Rectal Movement 
5.1   Introduction 
Incorporating organ motion in the treatment planning process is a challenging problem in 
the multi-fractional radiation treatment. In conventional treatment, the positional 
uncertainty of the CTV is handled by irradiating a larger volume to ensure the desired 
tumor dose coverage. This approach generally leads to increased normal tissue 
complications. The choice of the margin represents an empirical tradeoff strategy in 
radiation treatment. Rectal toxicity is one of the major limiting factors for dose escalation 
in external beam treatment of prostate cancer. The DVH of the rectum in the CT scan is 
commonly used as a predictive tool to estimate rectum complications and optimize 
treatment planning for prostate cancer. The dose volume constraints are predictors of 
rectal toxicity (Fiorino 2002, Foppiano, 2003, Mirabell 2003, Pollack 2002). Other 
parameters can be derived from DVH, such as the equivalent uniform dose (EUD) 
(Niemierko 1997, Wu 2002, Schwarz 2004) or the normal tissue complication probability 
(NTCP) (Lyman 1985), volume points at certain dose levels or the average dose 
(Boersma 1998, Jackson 2001, Skwarchuk 2000). However, both EUD and NTCP 
calculation need rectal DVH as input. While rectal DVH is affected by a number of 
uncertainties and limitations; for example, the dose distribution delivered to the rectum 
for prostate patient over the course of treatment is different fraction-to-fraction because 
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of the uncertainties such as patient setup error, rectal movement with respect to the bony 
anatomy, the delineation of the rectum, and the filling of rectum etc (Urie 1991, Webb 
1997, Fiorino 2002, Stasi 2006) and it is necessary to study the impact of organ motion 
on the rectal cumulative dose. 
Rectal movement causes considerable dose uncertainty over the course of treatment and 
leads to the differences between planned dose distribution and the dose distribution that is 
actually delivered to the rectum. The most important limitation of analyzing dose to the 
rectum lies in the fact that the rectum moves during the course of treatment, both by 
distorting and by moving bodily (eg, in the anterior-posterior direction). 
Studies of patients with multiple CT scans taken during treatment for prostate cancer 
(Balter 1995, Mageras 1996, Melian 1997, Lebesque 1995, Roeske 1995, van Herk 1995) 
showed that the rectum can move 1 cm in the anterior-posterior direction with respect to 
the bony anatomy. The calculation of dose is typically based on a rigid-body model of 
localization uncertainty involving translations (Killoran et al 1997) of the entire patient 
relative to a fixed dose distribution. Although the rectal movement is obvious for the 
rectum during a course of treatment for prostate cancer, it is not clear what kind of 
influences these variations might have on the predictive value of NTCP for the course of 
treatment. Few study reported the dosimetric consequences of the rectal movement. In 
this study, the rigid body model and serial portal imaging data were used to reproduce the 
cumulative dose distribution to the rectum considering internal organ motion using EUD 
per fraction method for prostate patients.  
The uncertainties of the internal organ motion result in variation of the delivered dose and 
can be evaluated fraction-to-fraction using EUD. The EUD in each fraction is called 
fractional equivalent uniform dose (EUDf) (Jiang et al 2006b). The rectal positional 
variations can be measured from portal imaging with gold seeds for prostate patients and 
rectal dose change per fraction can be expressed as EUDf deviation. This evaluation is 
performed by comparison of the fractional dose-volume-histogram, the rectal EUDf 
considering organ motion, and NTCP, with and without considering the internal organ 
motion. 
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5.2   Methods and Materials 
5.2.1    Patients and IMRT planning 
IMRT plans for prostate patients were made with prescribed dose D = 78 Gy (2 Gy per 
fraction). The DVH control points of the PTV and OAR were used according to the 
RTOG 0126 protocols (Michalski 2004). PTV includes the prostate plus a 10 mm margin 
in the anterior, left-right, superior-inferior directions, and 7mm in posterior direction. A 
3D dose distribution of one fraction planning was calculated using the Pinnacle3 
treatment planning system for five-field (5F: 0°, 72°, 144°, 216°, 288°)  and seven-field 
(7F: 40°, 80°, 110°, 250°, 280°, 310°, 355°) IMRT using 15 MV X-rays. Repeated portal 
images and good seeds dada have been used to characterize daily patient organ motion 
for 20 prostate patients. The patients were asked to have full bladder and empty rectum in 
treatment CT scanning. The geometric uncertainties of prostate and rectum were assumed 
to be rigid body; the calculation of rectal dose is based on a rigid-body model of 
localization uncertainty involving translations of the prostate and rectum relative to a 
fixed dose distribution. The rectum was shifted in AP direction according to the prostate 
AP motion. The prostate motion was covered by the PTV. The EUDf , cumulative dose to 
rectum and NTCP of the rectum were calculated for the course of the treatment.  
5.2.2   EUDf  (EUD per fraction) 
The survival fraction for a fractionated regimen of interest was obtained using the Linear-
Quadratic (LQ) model (Fowler 1989): 
[ ]fxddeSF )( 2βα +−=
                                                                (5.1) 
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Where d = dose/fraction; fx = number of fractions, integer. If the organ motion 
uncertainties were considered, the survival fraction can be expressed as:  
fxj SFSFSFSFSF ⋅⋅⋅⋅⋅= 21                                                        (5.2) 
Where j = 1, 2…39 are fraction number. For inhomogeneous dose distribution, di is the 

















                                                   (5.3) 
Where SF2Gy is the survival fraction at 2 Gy, N is number of dose calculation points 
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5.2.3   The Lyman-EUD model 
When considering non-uniform dose distributions, the DVH is converted to an effective 
homogeneous dose to total volume (D = EUD, ν = 1). The EUD algorithm uses the 











= ∑                                                       (5.5) 
where a = 1/n, n is a parameter that describes the volumetric dependence of the dose-
response relationship. EUDf for the rectum was calculated for each fraction according to 
the rectal AP movement over the course of treatment and was used to calculate the NTCP 
for the rectum.  
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erfNTCP                                      (5.6) 
where TD50 is the dose that causes 50% probability of injury, and m is the slope of the 
response curve at TD50, the steepest part of the curve. TD50 of 80 Gy, n of 0.12, and m of 
0.15 were use for rectum.  
5.2.4   Compare the effect of the rectal position and 
























Figure 5. 1: Rectal DVH versus position (P) and volume ((V) effects with reference to 
Random Phantom (1) P_Anterior: rectum moves 5mm in anterior direction (2) 
P_Posterior: rectum moves 5mm in posterior direction (3) V_increase: rectal volume 
increase 30% (4) V_decrease: rectal volume decrease (26%). 
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Rectal DVH of Rando Phantom for the 7F IMRT plan result is shown in Figure 5.1. In 
order to quantify the different effect of rectal volume and position changes on the rectal 
dose during the course of the treatment, the volume and position changes are considered 
separately: Only rectal position change 5mm in anterior direction (P_Anterior) and 5mm 
in posterior direction (P_Posterior); and only rectal volume increase 30% (V_increase) 
and decrease (26%) (V_decrease). Rectal volume increasing 30% resulted in the NTCP 
decreases from 7.59% to 6.88%, Rectal volume decreasing 26% resulted in the NTCP 
increases from 7.59% to 8.36%. Rectal position change resulted in NTCP change 
significantly compared to rectal volume changes, from 7.59% to 13.36% when rectum 
moves 5mm in anterior direction, and from 7.59% to 3.18% when rectum moves 5mm in 
posterior direction.  
Roeske et al (1995) reported rectum varied +/- 30% using CT scan for 10 prostate 
patients. The CT-based volumes’ study from Stasi et al (2006) showed a slight systematic 
variation of the rectal volume between planning and treatment with an average rectal 
volume increase of around 8 cm3 (range: 2–20 cm3) for 10 prostate patients. In our study, 
the volume increase from 77 cm3 to 100 cm3 (23 cm3 or 30% increase in volume) and 
decrease from 77 cm3 to 57 cm3 (20 cm3 or 26% decrease in volume) for Rando phantom 
revealed the possible range of rectal volume change simulated during treatment compared 
with Roeske and Stasi’s results. The increasing of rectal volume caused the NTCP 
decrease slightly, and the change is smaller comparing to the rectal position change. For 
the limitation of the data, only rectal position change was considered to evaluate the 
impact of rectal anterior-posterior movement on the cumulative rectal dose, EUDf and 
NTCP for 20 prostate patients in this study, and the results can be considered a surrogate 
for the cumulative rectal dose for a full treatment course. 
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5.2.5  Rectal anterior-posterior movements for 20 
patients 
The range of prostate motion varied significantly and the comparisons among studies are 
complicated due to different procedures and methods used by researchers. Organ motion 
was reported to be the result of pressure from bowel gas, feces, and urine in the urinary 
bladder (Lebesque 1995, van Herk 1995, Roeske 1995, Melian 1997, Padhani 1999, 
Stroom 2000). Additionally, high variability was noted in many of the studies due to 
different patient population sizes, different rectum and bladder states (full vs. empty), and 
differences in the number of measurements taken, methods of measurement collected, 
and time between measurements (Alasti 2001, Wu 2001, Huang 2002, Litzenberg 2002, 
Nederveen 2002, Deurloo 2005, Wong 2005). Motion of the prostate in the anterior-
posterior and inferior-superior directions was significantly larger than motion in the left-
right direction (Tinger 1998, Zelefsky 1999, Alasti 2001). The same result was revealed 
in our study using gold seeds and every day portal imaging for 20 prostate patients as 
shown in the Figure 5.2. In this 20 patients group, for patient #6, most of the prostate AP 
motions are in the anterior direction with mean = - 3.15 mm (anterior direction) and SD = 
2.15 mm (P6: Prostate: 83.6 cm3; Rectum: 61.77 cm3; Bladder: 578.16 cm3). While for 
patient #7, most of the prostate AP motions are in the posterior direction with mean = 
2.40 mm (posterior direction) and SD = 2.67 mm (P7: Prostate: 79.2 cm3; Rectum: 83.44 
cm3; Bladder: 278.88 cm3). These two patients’ results are shown as representatives for 
evaluating rectal dose fraction-to-fraction and all the patients’ results for the dose 
gradient, NTCP, and cumulative dose to the rectum considering organ motion are also 
listed and discussed. 
 















































































































































































































































































































































































































Figure 5. 2: Prostate anterior-posterior motion relative to bony anatomy for 20 patients 
 
   138





















































0 50 100 150 200



































Figure 5. 3: Data for patient 6 and 7 (a) Simulated rectal DVHs including rectal motion 
(planning DVH in bold) for 7F_IMRT; and (b) rectal fractional EUD change (%) for the 
course of treatment for 5F and 7F IMRT plans 
The rectal DVHs per fraction considering rectal movement for 7F plan are shown in the 
Figure 5.3(a). The fractional EUDf was calculated from rectal DVHs and EUDf changes 
relative to planning EUD are shown in Figure 5.3(b) for 5F and 7F plans. Because most 
of the rectum movements are in the anterior direction for patient 6, the most rectal 
fractional EUDf  changes are positive (EUDf increased) for both 5F and 7F IMRT plans 
in Figure 5.3 P6(b).  The fractional EUDf change for 7F plan is higher than that of 5F 
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plan. While for patient 7, the most rectal fractional EUDf changes are negative (EUD 
decrease) for both 5F and 7F IMRT plans in Figure 5.3 P7(b) because most of the 
motions are in the posterior direction, also the fractional EUDf change for 7F plan is 
much lower compared to 5F plan. 
The rectal DVHs for 5F and 7F are compared and shown in Figure 5.4(a) for both patient 
6 and 7. The rectal DVH is lower for 7F plan compared with 5F plan. For patient 6 in 
Figure 5.4 P6(b), NTCP increases for both 5F and 7F IMRT plans considering rectal 
movement due to most of the rectal movements are in the anterior direction, while for 
patient 7 in Figure 5.4 P7(b), NTCP decreases for both 5F and 7F IMRT plans 
considering rectal movement because most of the rectal movements are in the posterior 
direction for patient 7. 
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Figure 5. 4: Data for patient 6 and 7 (a) rectal fractional DVHs for 5F and 7F IMRT 
plans (b) Rectal NTCP changes with treatment fraction. 
5.2.7   Dose Gradient and rectal NTCP for 20 patients 
The profiles in AP direction (a) and the direction 15o from AP direction (b) show that 7F 
plan have much lower dose in the dose region from 40 Gy – 60 Gy than that of 5F plan as 
shown in Figure 5.5. There is plateau around 50 Gy for 5F plan in the posterior direction 
and the dose profile for 5F plan is the higher around the posterior direction. The dose 
gradient is defined as the derivation of dose along specific direction and denoted by the 
term G(Gy/cm)= rD v∂∂ / , where rv is the vector. The dose gradient used in this study is 
the absolute dose gradient and can be derived from dose profile to indicate the slope of 
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the dose fall in that direction. The magnitude of the dose gradient will tell how fast the 
dose falls in the specific direction. The local maximum dose gradient is the steepest slope 
of dose profile outside of planning target volume. But for 5F plan, the plateau divided the 
posterior profile into two parts, the two parts were analyzed and the average maximum 
dose gradient was used. The local maximum dose gradient from profile (a) and (b) were 
calculated and averaged for both 5F and 7F plans.  
Maximum dose gradient for 7F IMRT plan is higher than 5F IMRT planning for all the 
20 patients. In Figure 5.6, the larger gradient difference for 7F and 5F IMRT planning 
occurs in patients #2, #8, #11, #17 and #19, in which the patients #2, #8, #11 and #17 
have rectal volume over 100 cm3. The planning rectal NTCP is lower for these patients, 
especially for 7F IMRT planning as shown in Figure 5.7.  
Rectal NTCP for 5F and 7F IMRT planning is shown in Figure 5.7. The mean NTCP is 
6.8±1.7 % for 7F planning, and 9.2±1.7 % for 5F planning. NTCP calculation is based on 
relative volume, the patient with higher rectal volume had lower NTCP, such as patient 
#2, #8, #11 and #17, also the rectal DVH control points have the potential to be lowered 
further without compromising PTV to obtain higher dose gradient and lower NTCP. 
The relationship of rectal NTCP and maximum dose gradient for all the 20 patients are 
shown in Figure 5.8. The NTCP decreased with the increasing of dose gradient for 5F 
and 7F IMRT plans. The correlation coefficient for the rectal NTCP and the dose gradient 
is - 0.71. 
 
 

































































Figure 5. 5: Dose profile close to posterior direction where the PTV and rectum overlap 
(a) 0o, and (b) 15o for patients 6 and 7. 
 
 


















































Figure 5. 7: Rectal NTCP for 5F and 7F IMRT treatment planning. 
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Figure 5. 9: EUD change versus rectal motion in mm steps (a) anterior and (b) posterior 
directions. 
In Figure 5.9, when rectum moves into the high dose region (anterior direction), EUD 
increased for both 5F and 7F IMRT plans comparing with the respective planning EUD, 
while when rectum moves out of the high dose region (posterior direction), the EUD 
decreased for both 5F and 7F plans comparing with the respective planning EUD. The 
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average EUD increase are 1.2% and 0.9% for 7F and 5F IMRT plans respectively when 
rectum moves anterior direction every millimeter, while the EUD decrease are 1.5% and 
1.0% for 7F and 5F IMRT plans respectively when rectum moves posterior direction 
every millimeter. The EUD change is higher for 7F IMRT plan comparing with 5F plan 



























Figure 5. 10: The rectal EUD change for the whole course of treatment considering 
rectal motion for 20 patients. 
The total rectal EUD changed comparing with the planning rectal EUD for the course of 
treatment because of rectal anterior-posterior motion. For the 20 patients group in Figure 
5.10, 45% of patients EUD increased, in which 5% of patients increased more than 2.5%, 
while 55% of patients EUD decreased, in which 10% of patients decreased 10%. The 
EUD increase and decrease are higher for 7F plan comparing with 5F plan because of 
higher dose gradient for 7F plan. For patient #6, most of the rectal motions are in the 
anterior direction (- 3.15 ± 2.15 mm) for the course of treatment. EUD increased most for 
patient #6 in these patients group. However for patient #7, most of the rectal motions are 
in the posterior direction (2.40±2.67 mm) for the course of treatment. EUD decreased 
most for patient #7 in these patients group. But the EUD increase and decrease are 
relative to the respective planning EUD. The planning EUD for 7F plan is lower than 5F 
plan. The final rectal NTCP are shown in Figure 5.11 for planning NTCP and NTCP 
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considering rectal motion. The cumulative rectal EUD increase or decrease for the course 
of treatment depends on the motion amplitude and frequency in anterior or posterior 
directions. However, the amplitude of increase or decrease of rectal EUD depends on the 
dose gradient in posterior direction. Higher dose gradient leads to higher EUD change for 
























































Figure 5. 11: The rectal NTCP of 5F and 7F IMRT plans for (a) static planning and (b) 
including rectal motion. 
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The planning rectal NTCP for 5F and 7F plans are shown in the Figure 5.11 (a). Because 
the fraction numbers are different for different patients, the NTCP changed from patient 
to patient, but comparing 5F and 7F plans for the same patient, NTCP is lower for 7F 
plan compared with 5F plan.  When considering rectal movement, although the EUD 
changed more for 7F plan compared with 5F plan no matter rectum moves in anterior or 
posterior directions, the final rectal NTCP in Figure 5.11(b) shows that rectal NTCP for 
7F plan is lower than 5F plan. 
Comparing rectal NTCP of planning results and considering rectal motion results for (a) 
7F and (b) 5F IMRT plans in Figure 5.12 for 20 patients, the results shows the rectal 
NTCP decreases for half of the patients and increases for the other for both 5F and 7F 
plans in the patient group. For patient #6, NTCP increased from 1.48% to 2.18% for 7F 
plan and from 1.71% to 2.36% for 5F plan for the total 33 fractions. For patient #7, 
NTCP decreased from 4.39% to 3.07% for 7F plan and from 6.11% to 4.90% for 5F plan 
for the total 37 fractions.  
Previous studies on late rectal toxicity after radiation treatment for prostate cancer are 
based on dose distribution established at treatment planning and fitted to clinical normal 
tissue tolerance using NTCP models as described by Lyman (1985), Kutcher (1991) and 
Burman et al (1991). Lebesque et al. (1995) , in a study of 11 prostate cancer patients 
with serial CT scans, observed that the variation of the high-dose rectal volume was 
relatively small and that the NTCP variation did not correlate with rectal filling. Hence, 
they concluded that NTCPs as estimated from the initial scan are representative for the 
whole treatment. Fenwick (2001a, 2001b) stated that dose distribution uncertainties 
within the rectum during a treatment course (e.g., owing to rectal volumetric changes) 
have only a marginal impact on fitting a NTCP mode for late rectal bleeding. However, 
few studies gave the cumulative dose to the rectum in multi-fraction treatment. In this 
study, rectal cumulative dose and NTCP changing with treatment fractions were reported 
and compared for 5F and 7F IMRT plans for 20 patients.  
 
 















































Figure 5. 12: Comparing rectal NTCP for static planning and planning including rectal 
motion for 20 patients (a) 7F and (b) 5F. 
Severe rectal late effects are mostly dose dependent, and influenced more strongly by 
rectal movement. The rectal fractional EUDf, defined by the present study, can be 
considered a surrogate for the rectal dose for each patient during a full treatment course. 
However, daily changes in rectal volume and the respective DVH during a treatment 
course are potentially clinically relevant and merit further evaluation. 
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5.3   Chapter Summary 
The EUDf model evaluates the rectal dose fraction-to-fraction. Rectal movement includes 
motion into and out of the high dose region of the PTV. EUDf increases when rectum 
moves in the anterior direction and decreases when rectum moves in the posterior 
direction. The amplitudes of EUDf increase and decrease are correlated with the dose 
gradient. Higher dose gradients lead to higher rectal EUDf change. 7F IMRT plans have 
higher dose gradients compared with 5F IMRT plans in the posterior direction and lead to 
higher EUDf change, including both EUDf increases and decreases. The increase or 
decrease of the cumulative rectal dose for the whole course of treatment depends on the 
motion amplitude and frequency in anterior or posterior directions.  
Rectal NTCP is lower for 7F IMRT plans compared with 5F IMRT plans. When 
considering rectal movement, including motion amplitude and frequency, for the whole 
course of treatment, the rectal NTCP decreases for half of the patients and increases for 
the other half for both 5F and 7F plans in the 20 patient group. The work in the thesis 
focuses on rectum; rectal wall will show a greater sensitivity to motion than rectum. This 
method provides a simple way to estimate the normal tissue complication probability 
dynamically by considering internal organ motion throughout the whole treatment course. 
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Chapter 6 
 
Summary and Conclusions 
6.1  Summary  
IMRT results in a steep decrease in dose outside the target and causes sensitivity to 
geometric uncertainties. The dominant uncertainties in conformal treatment are setup 
error and internal organ motion. Both can be reduced significantly by use of online image 
guidance. Geometric uncertainties and day-to-day variability in target position emphasize 
the need for image-guidance radiation therapy. Frequent imaging with patient 
repositioning during the course of treatment has become standard practice in radiation 
oncology.  
In this study daily EPI for localization of implanted fiducial markers (gold seeds) 
provided data for analysis of setup error and organ motion for 118 patients. The 
simultaneous time-course trends of prostate motion and setup error showed that prostate 
motion occurred independently from bony anatomy displacement during treatment. 
Additional analysis revealed that the prostate motion correlates with bladder and rectum 
filling and setup error correlates with body size. A margin around the PTV is needed to 
account for internal organ motion after correcting for setup error using bony landmarks. 
The margin was determined according to the specific setup technique. For a conventional 
beam setup without image guidance, both setup error and organ motion should be 
considered. For correction of daily bony setup error by EPID without fiducial markers, a 
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margin should be considered to account for internal organ motion. Although the use of 
fiducial markers for positioning correction is reliable, a margin should be included to 
account for intra-fraction organ motion during treatment and other uncertainties. The 
margin also depended on treatment technique. For a four-beam box, 95% coverage is 
required according to the report ICRU-62 (ICRU 1999). For IMRT with correction of 
inter-fraction tumor motion, a 4mm margin should be used for intra-fraction motion and 
other uncertainties. Daily electronic portal images with implanted gold seed fiducials 
provided an effective way to verify and correct the position of the target immediately 
prior to radiation delivery for prostate radiation therapy. Significant reduction in both 
setup error and organ motion was achieved with this system. 
IMRT generates high dose gradients between the PTV and OARs. Treatment accuracy 
depends on both setup errors and organ motion that need to be precisely evaluated for 
individual patients. The dose gradients and motion PDF were used to evaluate the effect 
of internal organ motion for IMRT treatment planning of prostate cancer. The dose 
distribution including geometric uncertainties depended on the static IMRT dose gradient 
and motion PDF. The blurred dose gradient was calculated from the static dose gradient 
convolved with the PDF.  The dose including geometric uncertainties was obtained by 
integration of blurred dose gradient along specific directions. For the section of the dose 
profile where the dose gradient is near zero inside the PTV, there was minimal impact on 
the blurred dose for the internal organ motion, while for the section of the profile at 
outside edge of the PTV where the dose gradient is the steepest, there was maximal 
impact for internal organ motion. The dose including geometric uncertainties can also be 
determined from integration of the static dose convolved with the derivative of the PDF. 
This method was not investigated in this thesis because the primary objective was to 
provide a more fundamental understanding of the inclusion of geometric uncertainties 
using dose gradient. 
The blurred dose gradient was maximized by manually optimizing the dose objective 
function using DVH control points, or by reducing geometric uncertainty with corrective 
verification imaging. A parameter defined as the PMDD was introduced to characterize 
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the relationship of mean dose deviation and dose gradient. The PMDD depended on the 
dose gradient and motion PDF. OMDS was defined as the rate of change in PMDD with 
SD of Gaussian PDF and was found to increase with the LMDG in anterior, posterior, left 
and right directions. Due to common inferior and superior field borders of the field 
segments, the sharpest dose gradient occurred in the inferior region or both the superior 
and inferior regions of the perimeter of the target volume. Thus, prostate motion in the 
superior-inferior direction produced the highest dose difference. Verification of organ 
motion in the inferior direction is essential.  
Lower rectal NTCP was achieved by either selecting smaller margin or creating steeper 
dose gradient between PTV and rectum. Rectal complication probability was evaluated 
using spatial dose distributions and a dose gradient analysis. In the transverse plane, 
LMDGs exhibited a large variation for five-field plans and were lowest in the posterior 
direction. Dose objective function used for IMRT optimization did not necessarily 
produce higher dose gradient in all directions and could result in considerable variability 
depending on beam numbers and beam directions. The numbers of beams, beam 
direction, DVH control points, and the choice of optimizer had important effects on the 
dose gradients. In general, the dose objective function including desirable dose 
constraints should be satisfied. However, the conformality index and the magnitude 
variability in the dose gradient between the PTV and OAR depended on the number of 
beams, beam directions in the plan and on the performance characteristic of the DMLC. 
The LMDG was determined from reliable rectal dose–volume constraints for IMRT 
inverse-planning in vicinity of the posterior direction in the sagittal plane. Relative to the 
five-field plans, the seven-field plans demonstrated a higher LMDG in the posterior 
direction and also lower NTCP. The main advantage of IMRT is creating high dose 
gradients in more optimal locations with respect to normal tissues and targets. LMDG 
were achieved either by modifying the planning technique or adjusting rectal DVH 
control points. With lower rectal DVH control points, a higher LMDG in the posterior 
direction was obtained for both five-field and seven-field plans. A steeper dose profile 
and higher LMDG between PTV and rectum worked well to maintain TCP and reduce 
NTCP. The LMDG in vicinity of the posterior direction should be high enough to ensure 
that the dose falls off quickly to avoid high rectal dose. Relative to a five-field plan, the 
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seven-field plan demonstrated a higher LMDG in the posterior direction and resulted in 
lower rectal NTCP. To achieve the higher LMDG, V70Gy ,V60Gy and V50Gy of the rectal 
DVH are below 21%, 32% and 48%, respectively. These values were lower than RTOG 
guidelines (25%, 35% and 55%, respectively) and did not compromise the dose 
distribution elsewhere. 
Cumulative rectal dose was analyzed in an effort to identify features associated with an 
increased rectal complication probability. Rigid body rectal motion was evaluated 
fraction-to-fraction using equivalent uniform dose per fraction. Positional variations of 
the rectum were measured from portal imaging using gold seeds for 20 prostate patients 
and the rectal dose deviation was expressed as EUDf deviation. Rectal movement 
included movement in and out of the high dose region of PTV. The amplitudes of EUDf 
increase and decrease were correlated with the dose gradient. A higher dose gradient led 
to higher rectal EUDf change. Seven-field IMRT plans had higher LMDG compared to 
five-field IMRT plans in the posterior direction and led to higher EUDf change, including 
both EUDf increase and decrease. The increase or decrease of the cumulative rectal dose 
for the course of treatment depended on the dose gradient in vicinity of posterior 
direction, motion amplitude and frequency in anterior or posterior directions. Rectal 
NTCP was lower for seven-field IMRT plans compared with five-field IMRT plans. 
When considering rectal movement for the whole course of treatment, the rectal NTCP 
decreased for half of the patients and increased for the other half when compared to the 
NTCP from the static plan for both techniques (as calculated from the motion amplitude 
and frequency in anterior or posterior direction). This method provided a simple way to 
estimate the NTCP by considering internal organ motion throughout the whole treatment 
course. 
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6.2  Conclusions 
A Gaussian PDF is reasonable for modeling geometric uncertainties as indicated by the 
clinical IGRT patient study in Chapter 2. The PDF is patient specific and group SD 
should not be used for accurate treatment planning for individual patients. In addition, 
individual SD should not be determined or predicted from small imaging samples 
because of random nature of the fluctuations. Frequent verification imaging should be 
employed in situations where geometric uncertainties were expected and cumulative PDF 
data could be used for re-planning to assess accuracy of delivered dose. Group statistical 
data is useful for determining worst case discrepancy between planned and delivered 
dose. The margins for the PTV should ideally represent true geometric uncertainties. The 
measured geometric uncertainties were used in this thesis to assess PTV coverage, dose 
to OAR, EUDf and NTCP. 
The dose distribution including geometric uncertainties was determined from the integral 
of the blurred dose gradient along a specific direction relative to the motion. In general, 
the directions are arbitrary, but for prostate motion, it was convenient to use conventional 
orthogonal directions. The blurred dose gradient was obtained from the convolution of 
the static dose gradient with the PDF. The effect of organ motion on the dose gradient 
showed that geometric uncertainties reduce the planned dose gradient and cause a blurred 
dose gradient (Chapter 3). The blurring of dose gradient was minimized by improving 
individual LMDGs in the static plan or by reducing geometric uncertainty with corrective 
verification imaging. The LMDG was initially determined via optimization of the dose 
objective function, and was improved by manually adjusting rectal DVH constraints or 
by modifying beam angle and number (Chapter 4). Static dose was insufficient to assess 
PTV coverage and the dose to OAR. The inclusion of geometric uncertainties was 
required for close agreement between planned and delivered dose. Minimum SD is used 
when geometric uncertainty was corrected with verification imaging. Maximum SD was 
used when the geometric uncertainty was known to be large and difficult to manage. The 
maximum SD was 4.38 mm in AP direction, 2.70 mm in LR direction and 4.35 mm in SI 
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direction. The minimum SD was 1.1 mm in all three directions if less than 2 mm 
threshold was applied for uncorrected fractions in every direction. 
EUDf is a useful QA parameter for interpreting the biological impact of geometric 
uncertainties on the static dose distribution. EUDf has been used as the basis for the 
NTCP evaluation in the thesis (Chapter 5). Relative NTCP values were useful for 
comparative QA checking by normalizing known complications (e.g. reported in the 
RTOG guidelines) to specific DVH control points. The increase or decrease of the 
cumulative rectal dose for the course of treatment depended on the dose gradient in 
vicinity of the posterior direction, motion amplitude and frequency in anterior or 
posterior directions. For prostate cancer patient, rectal complication was evaluated from 
RTOG clinical trials, and detailed evaluation of the treatment techniques (e.g. dose 
prescription, DVH, number of beams, beam angles). Treatment plans that did not meet 
DVH constraints represented additional complication risk. Geometric uncertainties 
improved or worsened rectal NTCP depending on individual internal organ motion within 
patient. 
6.3   Recommendations for future Work 
The inclusion of geometric uncertainties in treatment planning and delivery as described 
in the thesis is based on the determination of LMDG and motion PDF. New imaging 
technologies, e.g. CBCT, will likely provide improvement in the determination of PDF. 
In addition, by including the dose gradient explicitly in the dose objective function, it will 
likely be possible to obtain high LMDG without additional adjustment of the DVH 
control points. These concepts are described briefly in the following sections.  
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6.3.1     CBCT and other emerging verification 
imaging technologies 
Advancements in linear accelerator design, especially the introduction of kilovoltage X-
ray tubes and flat detectors have made CBCT available. This has recently been installed 
at GRRCC. CBCT offers opportunities for IGRT data collection and deformable model 
research for both target and OAR. CBCT and other emerging verification imaging 
technologies can be used to better characterize motion PDF for tumor and OAR.  
Unlike the relatively rigid body motion of human bony anatomy, physiological actions 
can cause non-rigid motion or deformation of human tissues. A common restriction of 
organ motion study is the absence of a full 3D description of the organ deformation 
because this deformation is often expressed in a variation of volume only. To incorporate 
internal organ motion into the treatment planning for treatment evaluation and 
optimization, the reconstruction of a cumulative dose distribution in a deforming organ 
should be solved. For IGRT, it is essential to know the relative magnitude of translations, 
rotations, and shape variation such that the most appropriate correction strategy can be 
chosen. The most critical step in solving the problem is to track the displacement of each 
volume element in the organ between moments of dose delivery. Tracking individual 
elements in a deformable organ requires basic information of organ shape before and 
after organ motion. To predict the distribution of patient-specific organ motion, the organ 
volume in the daily CBCT scans acquired during the treatment process can be used. Due 
to the non-rigid nature of organ motion, the volume elements in the organ should be 
registered between any pair of organ volumes before, during, and after motion. 
 
   158
6.3.2    4D CT and respiratory motion 
One potential application of image-guided radiotherapy is to track the target motion in 
real time and then deliver adaptive treatment to a dynamic target by DMLC tracking or 
respiratory gating. For successful implementation of real-time beam tracking or beam 
gating, the precise location of a moving tumor or organ must be determined reliably from 
separate imaging system. Stereoscopic diagnostic x-ray imaging systems can provide 
precise 3D location information for a moving tumor through real-time x-ray imaging of 
fiducial markers during the treatment. Such systems provide a direct way for internal 
tumor and organ motion assessment and correction. The Cyberknife (Accuray Inc., 
Sunnyvale, CA) system uses orthogonal x-ray imaging to update their internal/external 
correlation for tumor tracking. Advanced radiation treatment tools, such as beam 
tracking, respiratory gating and DMLC, promise to improve the accuracy of radiation 
delivery to moving tumors.  
The breathing motion for lung patients can be considered using dose gradient analysis by 
determining the correlation between the respiratory motion kernel and dose gradient. The 
effect of respiratory motion on LMDG is a topic for further research. IGRT data 
collection and current methodology can be used as input for respiratory registration for 
both target and organs at risk. The framework for using LMDG and respiratory motion 
PDF remains useful for 4D CT or any other imaging technologies that can characterize 
the motion PDF. The method developed in this thesis can be extended to multi-
dimensional motion analysis by combining with data from other imaging modalities, such 
as 4D CT data. First, the motion parameters and motion patterns can be discovered to 
estimate a complete motion representation, and then the motion kernel results can be 
integrated into dose gradient analysis for tumor motion and predicting the effectiveness 
of IGRT.  
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6.3.3     Determining optimum LMDG between the 
PTV and OAR for other tumor sites 
The framework for using LMDG and PDF remains useful for CBCT or any other imaging 
technologies that can better characterize a GPDF or a non-GPDF. Even with Cyberknife 
technology, which ideally allows a beam to “track” target motion, there will always be an 
impact of target motion on the static plan – and the impact can be modeled with the 
framework presented in the thesis.  
IMRT is often used in conjunction with dose escalation. For the same cost functions, by 
analyzing the dose gradients versus plan type, and number and direction of beams, IMRT 
dose distributions determined from commercial planning system do not have steep (local 
maximum) dose gradient in every direction. However, IMRT can redistribute dose to 
achieve locally higher dose gradients in a particularly region, with potential loss of high 
dose gradient elsewhere. One advantage of IMRT is the ability to place dose gradients in 
more optimal locations with respect to normal tissues and/or targets, rather than explicitly 
achieving higher dose gradients all around the target. What is the optimal LMDG 
between the PTV and OAR for other tumor sites, such as head and neck, breast etc? The 
treatment strategies in these tumor sites using dose gradient analysis need to be assessed 
individually: (1) Qualify extension to other sites, spatial invariance of convolution kernel 
at surface; (2) PDF characterization separately for each treatment site. 
6.3.4     Inclusion of dose gradient and motion PDF 
into commercial IMRT optimization software 
The incorporation of the dose gradient and organ motion PDF into commercial IMRT 
optimization software is another potential research avenue for improving IMRT 
optimization. The optimization functions currently employed in IMRT are somewhat 
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insensitive to the creation of optimum LMDG between the PTV and OAR. Explicit 
parametric inclusion of the dose gradient between the PTV and OAR should help the 
optimizer find optimum LMDG and optimum DVH for a given plan. The feasibility and 
potential utility of IMRT scoring functions based on the optimal LMDG in vicinity of 
PTV and OAR will improve inadequacies of DVH-based evaluation of IMRT target 
coverage and dose to OAR. The dose gradient method used in this thesis is of value for 
overcoming the known limitation of DVH (i.e., lack of spatial and functional 
information). 
A higher dose gradient can also be achieved by adding a “shell” around PTV overlapping 
slightly with OAR. The dose can be constrained with the shell either by absolute or 
percentage dose value via a DVH. The “shell” can be added uniformly or non-uniformly 
around the PTV and the dose objective functions can be specified. Multiple shells can 
also be added to obtain the optimal dose gradient between PTV and OAR. The 
identification of a shell helps to define a region where the magnitude of dose gradient can 
be specified. 
6.3.5     Radiobiological considerations in IMRT 
optimization 
Niemierko (1997) introduced the concept of EUD in an attempt to establish a reliable 
scalar for reporting non-uniform dose results. To consider volume effects in a physical 
dose-constrained optimization, the planner can define additional DVH control points - 
EUD. The EUD is the homogeneous dose inside an organ that has the same biological 
effect as a given, heterogeneous dose distribution. For targets, the EUD is mostly 
determined by the lowest dose values. For OARs structured in parallel functional cells, 
the EUD is near the mean dose, whereas for OARs structured in serial cells, the EUD is 
more dominated by the maximum dose values. EUD was used for inverse treatment 
planning as a parameter in a sigmoid dose-effect curve that resembles the basic shape of 
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TCP/NTCP models. Because the EUD for OAR is an empirical model, the clinical 
relevance of EUD directly corresponds to the quality of the clinical data available. 
Planning based on TCP/NTCP models is still not widely used in clinical practice. The 
EUD is an intermediate concept between physical doses and TCP/NTCP models. The 
comparison of plans with varying PTV dose homogeneity is not reliable using mean dose 
alone, but the use of EUD has the potential to overcome this problem as it considers the 
contributing effect of each part of the PTV dose distribution. For fractionated treatments 
where the mean dose to the PTV per fraction is varying due to geometric uncertainties, 
both EUD and TCP showed little variation with the degree of dose non-uniformity. For 
other time dependent factors, such as fractionation rate and cell repopulation times, TCP 
again showed significant variation relative to EUD. The relative insensitivity of EUD 
implies that this index will be useful for dose evaluation when biological parameters are 
not known with accuracy, for the study of the radiobiological based optimization 
objective and dose gradient. Biological IMRT plans optimization should be evaluated 
using the dose gradient to determine the level of sensitivity of EUD to model parameters 
including TCP and NTCP. 
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